ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA

Abstract: A process for inhibiting sulfide production by sulfate-reducing bacteria by contacting certain anthraquinones with the medium containing the sulfate-reducing bacteria is disclosed, as well as an automated screening test for such inhibition.

Description: TITLE ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of U.S. Patent Application Serial No. 07/510,763, filed April 18, 1990. FIELD OF THE INVENTION The first aspect of the invention is the novel discovery that many anthraquinones, or the corresponding anthraquinol or tetrahydroanthraquinone derivatives thereof, inhibit sulfide production from sulfate- reducing bacteria and are thus potentially useful chemicals for treating industrial situations where biological sulfide generation is a problem. Examples include the prevention of souring of oil wells with hydrogen sulfide or the contamination of surface operations such as pipelines, and storage tanks with hydrogen sulfide. The second aspect is the relative • specificity of the anthraquinones, anthraquinols or tetrahydroanthraquinones for the process of respiratory sulfate reduction. This aspect extends the useful application of these inhibitors to situations where only sulfate-reducers should be inhibited, but not other bacterial types, as for example, in sewage treatment where bacterial digestion is desirable but sulfide generation is not, or in the utilization of biomass for the generation of fuel gases where hydrogen sulfide is a deleterious contaminant, or in the agricultural sphere where sulfide generation and consequent soil alkalinity may be a problem for rice cultivation. Hereinafter, the term "anthraquinone(s) " as used.in this application is defined to include anthraquinone compounds, the corresponding anthraquinol derivatives, the corresponding tetrahydroanthraquinone compounds, the corresponding octahydroanthraquinone compounds, and the reduced derivatives thereof. It is proposed that the anthraquinones are a novel treatment for the problem of hydrogen sulfide pollution by virtue of their relatively benign environmental impact, which is due to their relatively specific toxicity for respiratory sulfide generation. As a consequence, these compounds may be useful in treating situations that are incompatible with the use of broad- spectrum biocides. BACKGROUND OF THE INVENTION A recent review by iddel (1986) in Anaerobic Bacteria in Habitats Other Than Man, pp 157-184, Eds. Barnes and Mead, Blackwell Scientific Publications, includes as sulfate-reducing bacteria the genera: Pesylfovjbrio, pesulfptomacυluπt, Desulfobacter. Pesvlfp vlbus, DesulfococeuB, Desulfonema. PegylfQSgtrcina and Thβrmodesulfobacterium. Significant inter- and even intra-generic differences exist in terms of morphologies, ecological niches, and metabolic capabilities. However, all respiratory sulfate-reducing bacteria are strict anaerobes which are poisoned by oxygen. The preponderance of isolates are eubacterial and classified as Desulfovibrio although extremely thermophilic archaebacterial sulfate-reducers have been isolated from undersea volcanoes (Stetter et al., 1987 Science 236:822-825) . Thus, the term sulfate-reducer encompasses a broad spectrum of organisms across both eubacterial and archaebacterial branches of bacterial phylogeny. The metabolic capabilities of the genus Desulfovibrio reflect the range of available niches. Utilization of sulfate as an electron sink and respiratory substrate is the characteristic and predominant mode of energy generation. However, nitrate, elemental sulfur, fumarate and other sulfur oxy-acids, when present, can also serve in a similar capacity for a few species. These bacteria are specialists adapted to use the metabolic end-products of primary degradative bacteria for electron and carbon sources as described by Odom et al., 1981 in Trends in the Biology of Fermentations for Fuels and Chemicals, Eds. Hollaender, Rabson, Rogers, Pietro, Valentine, and Wolfe, Plenum Publishing and Odom et al., 1984 Ann. Rev. Microbiol. 38:551-592. Organic acids such as lactate, formate, and pyruvate, alcohols such as ethanol, and molecular hydrogen are the preferred electron sources for sulfate reduction. Acetate, which is the metabolic end-product of the Desulfovibrio P can be utilized by Desulfobacter as an electron donor with carbon dioxide as the sole end product (Stetter et al., 1987 Science 236:822-825). Thus, the sulfate-reducers can effect total mineralization of organic matter from the level of alcohols and acids to carbon dioxide. The sulfate-reducers play a special role in methane formation as it occurs in sewage treatment and freshwater bogs. In these situations, where sulfate concentrations are very low, the sulfate-reducer enters into a symbiotic relationship with methane-producing bacteria (methanogen) wherein the sulfate-reducers actually produce hydrogen from organic acids and alcohols only if the hydrogen is continuously consumed by the methanogen. This important process, termed interspecies hydrogen transfer, is a vital link in the food chain from complex polymers to methane (Odom et al., 1981 in Trends in the Biology of Fermentations for Fuels and Chemicals, Eds. Hollaender, Rabson, Rogers, Pietro, Valentine, and Wolfe, Plenum Publishing) . The most intensively studied aspect has been hydrogen metabolism due to its inherent relationship with methane (fuel) generation from biomass. Similarly, the implication of microbial hydrogen uptake in the phenomenon of anaerobic corrosion of steel according to the theory of cathodic depolarization has stimulated research into the the hydrogen metabolism of sulfate- reducers as well as other microbial types (Von Wolzogen Kuhr et al., 1934 Water 18:147-165, Odom et al., 1984 Ann. Rev. Microbiol. 38:551-592, Pankhania et al., 1986 J- Gen. Microbiol. 132:3357-3365, and Ringas et al., 1987 Corrosion Engineering 44 #6:386-396) . There are currently approximately 130 different industrial biocide products registered with the U.S. Environmental Protection Agency which are produced by over a 100 different companies in the U.S. alone. The leading biocides are halogenated compounds, which make up 35% of total sales, while quarternary detergents and phenolics represent 22% of total sales. Organometallic compounds, inorganic compounds, aldehydes, anilides, and organosulfur compounds make up the rest of the total. None of the known commercial chemicals are specific for sulfate-reducing bacteria, but many have demonstrated effectiveness against sulf te-reducers. Below are discussed some of the more commonly used inhibitors against sulfate-reducing bacteria. Organo-sulfur or sulfur-nitrogen compounds contain some of the more effective industrial biocides against sulfate-reducers. The isothiazoline containing compounds (produced by Rohm & Haas, Inc. under the name "Kathon®") are effective against, but not specific for, sulfate-reducers at 12 ppm (Oil and Gas Journal March 8, 1982, p253) . The thiocyanate containing compounds are effective in the range of 5-30 ppm (i.e. "Cytox®") . 2 ,2-Dibromo-3-nitrilopropionamide (DBNFA) is produced by Nalco, Inc. and is claimed to be particularly effective against sulfate-reducing bacteria at 3-12 ppm. This compound is also a good surfactant and corrosion inhibitor. Recently, Nalco, Inc. has introduced an oilfield biocide claimed to be effective against sulfate-reducers. The product is essentially metronidazole, which is a pharmaceutical originally used to treat Trichosomal infections. The compound is not specific for sulfate-reducers but i's claimed to be generally effective against anaerobic bacteria. Acids and aldehydes are also effective inhibitors of sulfate-reducers. Glutaraldehyde is widely used in water flooding situations at concentrations in the range of 100 to 2000 ppm. The sole U.S. producer is Union Carbide, Inc. with its own registered "Ucarcide®" formulation. Ucarcide® is claimed to protect oil fields from aerobic and anaerobic microorganisms including sulfate-reducing bacteria in water flooding situations, injection water, drilling and packer fluid. Formaldehyde, which is substantially cheaper, is also used in similar concentrations. These two compounds together comprise the major biocides used in the oil field. Acrolein, an extremely toxic compound, is also effective against sulfate-reducers and is reccommended for use at concentrations in the range of 1 to 15 ppm. Quarternary amines are a diverse group of compounds containing a quarternary nitrogen atom with long chain alkyl or aromatic substituents. In the oil field these compounds may act as both corrosion inhibitors and bacteriostatic agents. The compounds are used in this application in the 5-100 ppm range. At low concentrations these compounds may be bacteriostatic rather than bacteriocidal. The quarternary amines are generally less hazardous than many oil field biocides, but they must often be used in conjunction with more toxic biocides to enhance their effectiveness. Halogenated compounds, such as chlorhexidine (a biguanide) , (Hibitane® from ICI, Inc.) is a widely used, commercial, antimicrobial compound, and is known to be effective against a number of sulfate-reducing bacteria at concentrations of 1-10 ppm (Davies et al., 1954 Brit. J. Pharmacol. 9:192). This compound or its derivatives are generally effective against most bacterial types and are, therefore, nonspecific. Biguanides such as chlorhexidine appear to function by disruption of the cell membrane which causes release of cytoplasmic contents. There is no available data on any industrial use of this chemical to treat sulfate-reducing bacteria. Inorganic compounds, such as liquid chlorine, hypochlorites, chlorine dioxide and chloroisocyanurates are strong oxidizing agents, are often found as the active constituents in bleach, and have shown effectiveness in oil field situations against sulfate- reducing bacteria. Classical inhibitors of sulfate reduction such as mo÷lybdste, seienate, and fluorophosphate anions are analogues of sulfate and have been shown to interfere with the primary enzymatic step in the activation of sulfate, i.e., the adenosine 5'-triphosphate (ATP) sulfurylase reaction. Here an unstable phospho-analogue anhydride is formed in place of the phospho-sulfate bond. The consequence of this is that the bacterium eventually depletes its energy reserve of ATP via reaction with these analogues and death ensues (Taylor et al., 1979 Current Microbiol. 3:101-103 and Wilson et al., 1958 J. Biol. Chem. 233:975-981). Sulfate analogues have been used to inhibit sulfate-reduction at concentrations from 5-20 mM (i.e., 1000-4000 ppm molybdate) . These levels are impractical from an applications standpoint but the compounds have found use as research tools (Postgate, 1952 J. Gen. Microbiol. 6:128-142 and Saleh et al., 1964 J. Appl. Bact. 27*2:281-293). Furthermore, the sulfate analogues inhibit sulfate assimilation as it occurs in all bacteria and plants, as well as sulfate respiration, and, thus, are not truly specific for sulfate-reducing bacteria. Antibacterial activity associated with anthraquinones was first discovered in plant extracts of the genus Cassia. (Patel et al., 1957 Indian J. Pharmacol. 19:70-73). Subsequent investigations revealed that the active component of leaf extracts of Cassia sp. was Rhein or 4,5-dihydroxyanthraquinone-2- carboxylic acid (Anchel, 1949 J. Biol. Chem. 177:169-177). Subsequently, it has become apparent that many anthraquinones have antibacterial properties, however, it is equally clear that these compounds do not inhibit all bacterial types. In one study by F. Kavanaugh it would appear that gram positive organisms such as Bacillus sp. or Staphylococcus are sensitive to anthraquinones while gram negative species such as £. coli or Pseudomonas sp. are rather insensitive (Kavanaugh 1947 J. Bacteriol. 54:761-767). However, even among the gram positive bacteria, antibacterial effects are sporadic and unpredictable. For example, another study showed that 1,4,6,8- tetrahydroxyanthraquinone inhibited 4 species of Bacillus, one strain of Nocardia f one strain (out of four tested) of Streptomycβs and one of the Gram negative Proteus. The compound did not affect any species of £. £&li, Pseydomonas, Salmonella or Sarcina (Anke et al., 1980 Arch. Microbiol. 126:223-230 and Anke et al., 1980 Arch Microbiol., 126:231-236). A study by Bakola-Christianopoulou et al. 1986 Eur. J. Med. Chem.- Chim. Ther. 21*5:385-390, where the metal chelates of the anthraquinones were studied, showed that 1,8- dihydroxy-anthraquinone was inactive against £. aureus, £. s btiliS, £. StearO hermPPhiluS and £. aureus. In the same study 1,2-dihydroxyanthraquinone and l-amino-4- hydroxyanthraquinone were either inactive against these strains or required concentrations in excess of 100 to 1000 ppm for inhibition. These workers also concluded that the metal chelates were more active than the free uncomplexed compounds and that the compounds showed the most activity against the gram positive Bacillus sp. These results are typical of the published studies on the antibacterial activity of anthraquinones. Swiss Patent No. 614,466 of Mycogel Laboratories Inc., Brooklyn, New York, entitled Agent for Inhibiting the Growth of Bacteria in Culture Media and Use of the Agent describes the use of compounds derived from paraquinone or their hemiquinone or glycoside derivatives as agents for use in culture media for cultivating fungi and yeasts. The rationale disclosed w s that these compounds inhibit bacterial growth but not the growth of eukaryotic cells such as molds and yeasts. Preferred anthraquinone derivatives claimed include those substituted with methyl, hydroxymethyl, carboxyl, aldehyde and carboxyethyl groups. Haran et al., 1981 Isr. J. Med. Sci. 17*6:485-496, demonstrated that certain diaminoanthraquinone derivatives exhibited toxicity against gram positive cocci and that gram negative bacteria were rather insensitive. The mode of action of anthraquinones on bacterial metabolism is not clear and may be multitudinous. It is clear that the inhibitory effect is only observed with bacteria and not with plant, fungal or mammalian tissue, hence, the compounds are relatively non toxic to higher life forms. It is known that many anthraquinones interfere with bacterial DNA metabolism, presumably at the site of DNA directed RNA polymerase (Anke et al., 1980 Arch Microbiol., 126:231-236).). Anthraquinone- containing compounds have also been shown to inhibit itochondrial ADP transport (Boos et al., 1981 FEBS Lett. 127:40-44). It is also known that reduced anthraquinones may react chemically with oxygen to produce the highly toxic superoxide radical and this is generally very toxic to bacteria (Shcherbanovskii et al., 1975 Rastit. Resur. 11*3:445-454). The consensus from the existing literature is that anthraquinones are not generally antimicrobial. The organisms that are sensitive to anthraquinones have been Gram positive bacteria, in particular Bacillus sp. The anthraquinones do exhibit an array of unrelated and unpredicted biological effects as briefly listed above. The inhibition of sulfide production by anthraquinones is unreported in the literature and appears to be another example of an unpredicted and unrelated biological effect, particularly considering that the sulfate-reducers are Gram negative organisms. It is clear that sulfide pollution is a growing industrial and environmental concern for which there exists no truly effective or adequate treatment that is environmentally sound. The chemical treatments that are available have a number of shortcomings. Many of these chemicals are highly reactive with short effective lives as antimicrobials and therefore high concentrations are required. Secondly, due to their inherent toxicity, these compounds may pose a health hazard to the personnel using them. Thus a need exists for better means of controlling sulfide pollution. One key and important difference between existing chemicals and the compounds of the instant invention is the relatively unreactive nature of a number of anthraquinones as a group. In fact, 1,8-dihydroxy- anthraquinone (one of our most potent compounds) has been sold commercially as a laxative (see Physicians' Desk Reference, page 574 for Modane®, and page 575 for Modane Plus®) . Many anthraquinones, including derivatives of 1,8-dihydroxyanthraquinone, are naturally-occurring in a number of plants such as rhubarb (Rheum officinale) . Use of plant extracts include senna in Senakot® Tablet and Senokot-S® (see Physician's Desk Reference, pages 1596-1597), and casenthranol in Dialose Plus ® (see Physicians' Desk Reference, page 1979) . The specific inhibitory activity of the compounds of the present invention and their lack of toxicity to many other organisms opens up entirely new possiblities for use in various waste treatment situations where conventional biocides cannot be used. For example, the odor associated with sulfide pollution in sewage treatment is both a health hazard and an esthetic problem for many communities. More significantly, from the economic standpoint, concrete conduits are damaged from the aerobic oxidation of sulfide to sulfuric acid. This is a particular problem for cities such as Miami or Los Angeles where the distances involved in sewage transit at ambient temperatures mean long residence times, high metabolic activity and tremendous destruction of concrete structures. The current "state of the art" method to treat this problem is to precipitate the sulfide from solution using massive amounts of ferrous chloride. This alleviates the odor problem but does not remove the sulfide as a substrate for acid producing bacteria (Jameel 1988 Journal WPCF 61*2:230 and Dezha et al.. Journal WPCF 60*4:514). The instant invention is particularly advantageous for this kind of application. SΠMMΆBY OF THE INVENTION The present invention relates to a process for inhibiting sulfide production by sulfate-reducing bacteria comprising contacting certain anthraquinone compounds with the medium containing the sulfate- reducing bacteria. The present invention further comprises an automated process for the testing of compounds for inhibition of sulfide production by bacteria. BRIEF DESCRIPTION OF THE FIGURES Figure 1 is a schematic of an automated analyzer used to screen anthraquinones for inhibition of sulfide production. Figure 2 is a trace from an automated analyzer used to screen anthraquinones for inhibition of sulfide production. DETAILED DESCRIPTION OF THE INVENTION One object of this invention comprises a process to inhibit sulfide production by sulfate-reducing bacteria comprising contacting certain anthraquinones with the medium which contain the sulfate-reducing bacteria. The term "anthraquinone(s) " as used herein is as previously defined under Field of the Invention. Many anthraquinones are commercially available. The preparation of anthraquinol derivatives from anthraquinones is known to those skilled in the art. For example, l,8-dihydroxy-9-anthranol can be prepared by reduction of 1,8-dihydroxyanthraquinone using hydrogen and a nickel catalyst, K. Zahn and H. Koch, Chemische Berichte, 17B, 172 (1938) or by use of phosphorous and hydriodic acid. 1,2,10-Anthracenetriol can be prepared by reduction of 1,2-dihydroxy- anthraquinone using ammonium hydroxide and zinc, H. Roemer, Chemische Berichte, 14, 1259 (1881), C. Grabe and C. Thode, Liebig 's Annalen der Chemie, 349, 207 (1906) . These and similar reductions are summarized in Das Anthracen und die Anthrachinone, H. Houben, Georg Thieme pub., 1929, Leipzig, pp. ' 193-195. Reduction methods for preparation of hydroanthraquinones are found in Das Anthracen und die Anthrachinone, H. Houben, Georg Thieme, pub., 1929, Leipzig, pp 183-186. For example, the preparation of tetrahydroanthraquinones, and various reduced derivatives are described in U.S. Patents 1,967,862 issued July 24, 1934 and 4,642,393 issued February 10, 1987; Diels and Alder, Ber. , 62, 2337 (1929); Carothers et al., J. Amer. Chem. Soc , 54, 4071 (1932); and Euler et al., Ber. , 53B, 822 (1920). The activity of various anthraquinones in the inhibition of sulfide production by sulfate-reducing bacteria can be predicted based upon analysis of the substituents present. A total of 147 different active anthraquinones were named according to the rules found in the 7th Collective Index of Chemical Abstracts. Following this convention, a multiple linear regression analysis of the activity data resulted in the creation of formula (I) Activity - 28.1 + ∑ (coeff.) (I) wherein activity refers to the percent reduction of H 2 S production, 28.1 is a constant, and ∑ (coeff.) refers to the sum of the coefficient values. Coefficient values are given in the coefficients table. Table C, for each individual coefficient Ri through R- present in the anthraquinones represented by structure (A), or the corresponding derivatives thereof. As an example, the activity of the anthraquinone substituted as shown below is predicted to be 26.4 from the formula. The observed value is 26.0. Anthraquinones having substituents with positive values in the coefficient table increase activity while those that have substituents with negative values decrease activity. Anthraquinones having substituents whose coefficients yield positive activity in formula (I) are active and those with an activity above at least 21 in the formula are most active and preferred. Those having substituents whose coefficients yield a negative activity in formula (I) are not active. The compounds may possess some substituents having negative coefficients and still retain overall activity. These negative substituents can serve other purposes, such as increasing solubility. It should be noted that the standard deviation of regression for the formula is 20.7; therefore, the values calculated from the formula are ± 20.7. 14 Number of data points - 147 Standard deviation of regression 20.7 The abbreviations for the substituents are explained as follows: **C" refers to any alkyl or aryl group bound to the anthraquinone ring by a covalent carbon-carbon bond with the exception of carboxylic acid groups. "Carb" refers to any carboxylic acid group, CO∑H, bound to the anthraquinone ring. "N-amine" refers to any amino group, NR 3 .R 2 , where Ri and R 2 may be H or alkyl; "N-amine" also refers to NO 2 , diazonium, or NO groups since under the reducing conditions present, these are expected to be reduced to amine groups. R l O R3O "N-amide" refers to N-C-R 2 or N-S-R 4 groups, where O where Ri, R2, R3, R 4 may be H, alkyl groups or aryl rings. "N-aryl" refers to aryl amine groups, such as phenylamino, or a heterocyclic aromatic ring attached to the anthraquinone ring by carbon-nitrogen-carbon bonds. "O" refers to the hydroxyl group. "OR" refers to alkyl or aryl ethers. "S" refers to SO 3 H group. "Cl" and "Br" refer to the chloro and bromo groups. The number with each substituent refers to the position on the anthraquinone ring to which the substituent is attached. Anthraquinones or anthraquinone precursors or derivatives suitable for the inhibition of sulfide production by sulfate-producing bacteria in the process of the present invention include the following: N-[l-(9,10-dihydro-9,10-dioxo)anthracenyl]-N'-(1- mcthylethyl)i idodicarboriimidic diamide hydrochloride CA Reg. No.: None Source: E. I. du Pont de Nemours and Company 1-Aminoanthraquinone (97%) CA Reg. No. : 82-45-1 Source: Aldrich Chemical Co., Inc. 940 West Saint Paul Avenue Milwaukee, WI 53233 2-Aminoanthraquinone CA Reg. No. : 117-79-3 Source: Aldrich l-Amino-4-Hydroxyanthraquinone CA Reg. No. : 116-85-8 Source: Kodak Laboratory Chemicals Building 70 Eastman Kodak Co. 343 State Street Rochester, NY 14650 1,2-Diaminoanthraquinone CA Reg. No.: 1758-68-5 Source: Aldrich 2,6-Dihydroxyanthraquinone; Anthraflavic acid CA Reg. No. : 84-60-6 Source: Aldrich Anthraquinone-2-carboxylic acid (98%) CA Reg. No.: 117-78-2 Source: Aldrich 1,5-Dihydroxyanthraquinone; Anthrarufin (92%) CA Reg. No.: 117-12-4 Source: Pfaltz and Bauer, Inc. Division of Aceto Chemical Co., Inc. 172 East Aurora Street Waterbury, CT 06708 1,2-Dihydroxyanthraquinone; Alizarin CA Reg. No. : 72-48-0 Source: Aldrich 2,2'-[(9,10-Dihydro-9,10-dioxo-l,5- anthracenediyl)diimino.bis[5-methylbenzenesulfonic acid], di Na salt; Alizarine violet 3R CA Reg. No.: 6408-63-5 Source: Aldrich 1,2,5,8-Tetrahydroxyanthraquinone; Quinalizarin CA Reg. No. : 81-61-8 Source: Aldrich 4-Amino-9,10-dihydro-l,3-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid, monosodium salt; Nuclear fast red CA Reg. No.: 6409-77-4 Source: Aldrich 1,8-Dihydroxyanthraquinone; Danthron CA Reg. No. : 117-10-2 Source: Aldrich 2,2'-[(9,10-Dihydro-9,10-dioxo-l,4- anthracenediyl)diimino]bis[5-methylbenzenesulfonic acid],di Na salt; Acid green 25 CA Reg. No.: 4403-90-1 Source: Aldrich l-Amino-2,4-bromoanthraquinone CA Reg. No. : 81-49-2 Source: Pfaltz & Bauer 5-Chloro-l-anthraquinonylamine CA Reg. No. : 117-11-3 Source: Pfaltz & Bauer 2-Ethylanthraquinone (97+%) CA Reg. No. : 84-51-5 Source: Aldrich 1-Hydroxyanthraquinone (97%) CA Reg. No. : 129-43-1 Source: Aldrich 2-(Hydroxy ethyl)anthraquinone (97%) CA Reg. No.: 17241-59-7 Source: Aldrich l-Amino-4-methoxyanthraquinone CA Reg. No. : 116-83-6 Source: Aldrich l-Amino-6,7-dichloroanthraquinone CA Reg. No.: 5355-88-4 Source: Aldrich Benz[a]anthracene-7,12-dione (97%) CA Reg. No.: 2498-66-0 Source: Aldrich 1,8-Dihydroxy-3-methylanthraquinone; Chrysophanic acid CA Reg. No.: 481-74-3 Source: Aldrich 10- [ (3-Amino-2, 3, 6-trideoxy-alpha-L-lyxo- hexopyranosyl) oxy] -7, 8 , 9, 10-tetrahydro-6, 8, 11- trihydroxy-8- (hydroxyacetyl) -l-methoxy-5, 12- naphthacenedione hydrochloride; Adriamycin hydrochloride CA Reg . No . : 23214-92-8 Source : Aldrich 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2- anthracenecarboxylic acid; Rhein CA Reg. No.: 478-43-3 Source: Aldrich (8S-cis)-8-Acetyl-10[(3-amino-2,3,6-trideoxy-alpha-L- lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11- trihydroxy-l-methoxy-5,12-naphthacenedione hydrochloride; Daunomycin hydrochloride CA Reg. No.: 20830-81-3 Source: Sigma Chemical Co., Inc. P.O. Box 14508 Saint Louis, MO 63178 1,2, -Trihydroxyanthraquinone; Purpurin CA Reg. No. : 81-54-9 Source: Aldrich 1-Aminoanthraquinone diazonium salt CA Reg. No.: 16048-40-1 Source: K&K Laboratories Division of ICN Biomedicals, Inc. 4911 Commerce Parkway Cleveland, OH 44128 2,2*-Dimethyl-[1,1'-bianthracene]-9,9',10,10'-tetrone; 2,2'-Dimethyl-1,1*-bianthraquinone CA Reg. No.: 81-26-5 Source: Aldrich 3-(D-apio-beta-D-Furanosyloxy)-1,8-dihydroxy-6-methyl- 9,10-anthracenedione; Frangulin B CA Reg. No.: 14101-04-3 Source: Pfaltz & Bauer 2-Chloroanthraquinone 99% CA Reg. No. : 131-09-9 Source: Aldrich 1,5-Dichloroanthraquinone (96%) CA Reg. No. : 82-46-2 Source: Aldrich 1,4,5,8-Tetrachloroanthraquinone CA Reg. No. : 81-58-3 Source: K & K 1-Chloroanthraquinone CA Reg. No. : 82-44-0 Source: Aldrich 1,8-Dichloroanthraquinone (97%) CA Reg. No.: 82-43-9 Source: Aldrich 2-Bromo-3-methylathraquinone CA Reg. No. : 84-44-6 Source: Pfaltz & Bauer 2-(2,2,2-Trimethylpropionamido)anthraquinone CA Reg. No. : None Source: Aldrich 2, 6-Bis[2-(dimethylamino)ethoxy]-9,10-anthracenedione; Tilorone analog R11,043DA CA Reg. No.: 66686-31-5 Source: Sigma 2-Methyl-l-nitroanthraquinone CA Reg. No. : 129-15-7 Source: Lancaster Synthesis Ltd. P.O. Box 1000 Windham, NH 03087 l-Amino-9, 10-dihydro-9,10-dioxo-2-anthracenesulfonic acid; l-Aminoanthraquinone-2-sulfonic acid CA Reg. No. : 83-62-5 Source: Aldrich 9,10-Dihydro-5-nitro-9,10-dioxo-l-anthracenesulfonic acid; 5-Nitroanthraquinone-l-sulfonic acid CA Reg. No.: 82-50-8 Source: Aldrich 3-Chloro-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid; 2-Chloroanthraquinone-3-carboxylic acid CA Reg. No. : 84-32-2 Source: Pfaltz & Bauer Anthraquinone CA Reg. No. : 84-65-1 Source: Aldrich 1,8-Dihydroxy-3-(hydroxy ethyl)-anthraquinone; Aloe- e odin CA Reg. No. : 481-72-1 Source: Apin Chemicals, Ltd. Unit 1 Milton Trading Estate Near Abingdon Oxon 0X14 4RS United Kingdom 7 ,16-Dichloro-6,15-dihydro-5,9,14,18-anthrazinetetrone; 7,16-Dichloroindanthrone CA Reg. No.: 130-20-1 Source: K & K 1,2,3,4,5,8-Hexahydroxyanthraquinone; Alizarin cyanin CA Reg. No. : None Source: K & K 2,4,5,7-Tetrabromo-l,8-dihydroxy-9,10-anthracenedione; 2,4,5,7-Tetrabromochrysazin CA Reg. No.: 17139-66-1 Source: K & K 1,2,7-Trihydroxyanthraquinone; Anthrapurpurin CA Reg. No.: 602-65-3 Source: Pfaltz & Bauer 1,4, 5-Trihydroxy-2-methyl-9,10-anthracenedione; Islandicin CA Reg. No. : 476-56-2 Source: Apin 1,4,5,7-Tetrahydroxy-2-methyl-9,10-anthracenedione; Catenarin CA Reg. No.: 476-46-0 Source: Apin 1,8-Dihydroxy-3-methoxy-6-methyl-9,10-anthracenedione; Physcion CA Reg. No.: 521-61-9 Source: Apin 1,4,5,8-Tetrahydroxy-2-methyl-9,10-anthracenedione; Cynodontin CA Reg. No. : 476-43-7 Source: Apin 1,5,8-Trihydroxy-3-methyl-9,10-anthracenedione; Helminthosporin CA Reg. No.: 518-80-9 Sourc : Apin l-Hydroxy-2-[ (6-0-J5-D-xylopyranosyl-β-D- glucopyranosyl)oxy]-9,10-anthracenedione; Ruberythric acid CA Reg. No. : 152-84-1 Source: Apin 2-Phenoxy quinizarin-3,4'-disulfonic acid, di K salt CA Reg. No. : None Source: K & K (+,-)-l-Acetoxy-8-hydroxy-l,4,4a, 9a- tetrahydroanthraquinone CA Reg. No.: 73794-49-7 Source: Aldrich l-Amino-4-[ [4-[ (dimethylamino)methyl]phenyl]amino]- 9,10-anthracenedione; Basic Blue 47 CA Reg. No.: 12217-43-5 Source: Aldrich 1, 5-Bis (2-carboxyanilino) -9, 10-anthracenedione; Acridylic acid CA Reg . No . : 81-78-7 Source: Sandoz Chemicals 4000 Monroe Road Charlotte, NC 28205 1,8-Dihydroxy-9-anthranol; 1,8-Dihydroxyanthranol CA Reg. No. : 480-22-8 Source: Aldrich 1,2, 10-Anthracenetriol; Anthrarobin CA Reg. No.: 577-33-3 Source: Aldrich l-Amino-4-bromo-2-methylanthranquinone (99%) CA Reg. No. : 81-50-5 Source: Aldrich 1,4-Diaminoanthraquinone (97%) CA Reg. No. : 128-95-0 Source: Aldrich 2, 6-Diaminoanthraquinone CA Reg. No. : 131-14-6 Source: Aldrich l-Amino-4[4-[[4-chloro-6[[2, 3 or 4-sulfophenyl]amino]- l,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10- dihydro-9,10-dioxo-2-anthracenesulfonic acid; Reactive blue 2; Procion blue HB(S); Cibacron blue 3G-A; Basilen blue E-3G CA Reg. No.: 12236-82-7 Source: Aldrich Anthraquinone-1,5-disulfonic acid, di Na salt hydrate (95%) CA Reg. No.: 853-35-0 Source: Aldrich Anthraquinone-2,6-disulfonic acid, di Na salt CA Reg. No. : 84-50-4 Source: Aldrich Anthraquinone-2-sulfonic acid, sodium salt monohydrate CA Reg. No. : 131-08-8 Source: Aldrich 1,2-Bis[ (4-sulfophenyl)amino]-4-hydroxyanthraquinone; Alizarin blue black B CA Reg. No.: 1324-21-6 Source: Aldrich 3-Aminomethylalizarin-N,N-Diacetic acid CA Reg. No.: 3952-78-1 Source: Pfaltz & Bauer l-Amino-4-[[3-(ethenylsulfonyl)phenyl]-9,10-dihydro- 9,10-dioxo]-2-anthracene sulfonic acid, monosodium salt; Acid blue 215 CA Reg. No.: 14541-90-3 Source: Aldrich 1-(Methylamino)anthraquinone (98%) CA Reg. No. : 82-38-2 Source: Aldrich 2,2'-[(9,10-Dihydro-5,8-dihydroxy-9,10-dioxo-l,4- anthracendiyl)diimino]bis[5-methylbenzenesulfonic acid], di Na salt; Acid green 41 CA Reg. No.: 4430-16-4 Source: Aldrich 2,2'-[ (9,10-Dihydro-9,10-dioxo-l,4- anthracenediyl)diimino]bis[5-butylbenzenesulfonic acid]; Acid green 27 CA Reg. No.: 6408-57-7 Source: Aldrich 1,1'-Iminobis[4-amino]9,10-anthracenedione, sulfonated; Acid black 48 CA Reg. No.: 1328-24-1 Source: Aldrich l-Amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-2- anthracenesulfonic acid, Na salt; Acid blue 25 CA Reg. No. : 6408-78-2 Source: Aldrich 4-[ [4-(Acetylamino)phenyl]amino]-l-amino-9,10-dihydro- 9,10-dioxo-2-anthracenesulfonic acid, Na salt; Acid blue 40 CA Reg. No.: 6424-85-7 Source: Aldrich l-Amino-9, 10-dihydro-9,10-dioxo-4-[ [3[ [2- (sulfooxy)ethyl]-sulfonyl]ρhenyl]amino]-2- anthracenesulfonic acid, disodium salt; Remazol Brilliant blue R; CA Reg. No.: 2580-78-1 Source: Aldrich l-Amino-4 [ [3-[4,6-dichloro-l,3,5-triazin-2-yl)amino]-4- sulfophenyl]amino]-9,10 dihydro-9,10-dioxo-2- anthracenesulfonic acid; reactive blue 4 CA Reg. No.: 13324-20-4 Source: Aldrich 1-(9,10-Dihydro-9,10-dioxo-l-anthracenyl-l,2- hydrazinedisulfonic acid, di Na salt; (1- Anthraquinonyl)-1,2-hydrazine disulfonic acid, di Na salt CA Reg. No.: 54345-83-4 Source: K & K 9,10-Dihydro-5,6-dihydroxy-9,10-dioxo-l- anthracenesulfonic acid; Alizarin-5-sulfonic acid CA Reg. No.: 6373-42-8 Source: Tokyo Kasei Kogyo Co., Ltd. c/o CTC Organics 792 Windsor Street P.O. Box 6933 Atlanta, GA 30315 N-(4-Chloro-9,10-dihydro-9,10-dioxo-l- anthracenyl)benzamide; l-Benzamido-4-chloroanthraquinone CA Reg. No. : 81-45-8 Source: Aldrich l-Amino-4-bromo-9,10-dihydro-9,10-dioxo-2- anthracenesulfonic acid, Na salt; l-Amino-4- bromoanthraquinone-2-sulfonic acid, Na salt CA Reg. No.: 6258-06-6 Source: Aldrich 5 l-Amino-9,10-dihydro-4 [[(4-methylphenyl)sulfonyl]amino- 9,10-dioxo-2-anthracenesulfonic acid, Na salt; 1-Amino- 4-(p-toluenesulfonamido)anthraquinone-2-sulfonic acid, Na salt CA Reg. No.: 64981-00-6 Source: Aldrich - • ^ 9,10-Dihydro-9,10-dioxo-2,3-anthracenedicarboxylic acid CA Reg. No.: 27485-15-0 Source: Aldrich 1,1'-Iminobis(4-nitro-9,10-anthracenedione) CA Reg. No. : 128-88-1 Source: Pfaltz & Bauer 15 l-Amino-4-chloro-2-methylanthraquinone CA Reg . No . : 3225-97-6 Source : Aldrich 2 , 3-dimethyl-l , 4 -dihydroxyanthraquinone ; 2, 3- Dimethylquinizarin CA Reg . No . : 25060-18-8 20 Source : Aldrich 6-Methyl-l , 3, 8-trihydroxyanthraquinone; Emodin ( 99%) CA Reg . No . : 518-82-1 Source : Aldrich 1 , 4-Bis (methylamino) -anthraquinone 25 CA Reg . No . : 2475-44-7 Source : Aldrich N- (4-Amino-9, 10-dihydro-3-methoxy-9, 10-dioxo-l- anthracenyl) -4-methylbenzenesulfonamide; N- (4-Amino-3- methoxyanthraquinone-1-yl) -p-toluenesulf onamide; 1- Amino-2-methoxy-4- (p-tolylsuf onamido) anthraquinone CA.Reg . No . : 81-68-5 3 ^ Source : Aldrich 35 π,l , -Bianthracene]-9,9'10,10 , -tetrone; 1,1'- Bianthraquinone CA Reg. No. : 914-20-5 Source: Columbia Organic Chemical Co., Inc. P.O. Box 1045 Camden, SC 29020 6,7-Dichloro-l,4-dihydroxyanthraquinone (97%) CA Reg. No.: 1225-15-6 Source: Aldrich 2-[ [9,10-Dihydro-4-(methyla ino)-9,10-dioxo-l- anthracenyl]amino]-5-methyl-benzenesulfonic acid, monosodium salt; Alizarine astrol B-CF CA Reg. No.: 6408-51-1 Source: Tokyo Kasei Kogyo Co., Ltd. 2,8-Diphenyl-anthra[2,1-d:6,5-d']bisthiazole-6,12-dione; Indanthrene yellow GCN CA Reg. No.: 129-09-9 Source: Tokyo Kasei Kogyo Co., Ltd. 2-Methoxy-3-methyl-9,10-anthracenedione CA Reg. No.: 17241-42-8 Source: Aldrich 1,4-Bist (1-methylethyl)amino]-9,10-anthracenedione; 1,4-Di(isopropylamino)anthraquinone CA Reg. No.: 14233-37-5 Source: K & K 1,4-Bis[ (2 , 4 , 6-triethylphenyl)amino]-9,10- anthracenedione; 1,4-Bis(2,4, 6- triethylanilino)anthraquinone CA Reg. No.: 116-74-5 Source: K & K 1-(2-Hydroxyethyl)amino-4-methylaminoanthraquinone; Disperse blue 3 CA Reg. No.: 2475-46-9 Source : Aldrich 1, 4-Bis [ (4-methylphenyl) amino] 9, 10-anthracenedione ; Solvent green 3 CA Reg . No . : 128-80-3 Source : Aldrich 2-Amino-3-hydroxyanthraquinone CA Reg . No . : 117-77-1 Source : Tokyo Kasei Kogyo Co . , Ltd . 1-(Bromothio)anthraquinone CA Reg. No. : None Source: Aldrich 1,8-Bis(phenylmethoxy)-9,10-anthracenedione; 1,8-Dibenzyloxyanthraquinone CA Reg. No.: 69595-66-0 Source: Aldrich l-Amino-2-(2-aminoethylthio)-4-hydroxyanthraquinone CA Reg. No. : None Source: Aldrich ' l,4-Bis(pentylamino)-9,10-anthracenedione; Oil blue N CA Reg. No.: 2646-15-3 Source: Aldrich l-Amino-2-bromo-4-hydroxyanthraquinone CA Reg. No. : 116-82-5 Source: Aldrich 2-Propionamidoanthraquinone CA Reg . No . : None Source : Aldrich l, 4-Diamino-2 , 3-bis (2-phenoxyethoxy) anthraquinone CA Reg . No . : 41313-11-5 Source: Aldrich N-(5-Chloro-9,10-dihydro-9,10-dioxo-l- anthracenyl)benzamide; l-Benzamido-5- chloroanthraquinone CA Reg. No. : 117-05-5 Source: Aldrich Anthraquinone-1-arsonic Acid CA Reg. No. : None Source: K & K N,N'-[Iminobis(9,10-dihydro-9,10-dioxo-4,1- anthracenediyl) ]-bisbenzamide; 4,4'-Dibenzamido-1,1'- dianthrimide CA Reg. No. : 128-79-0 Source: Aldrich 1, ,5,8-Tetraaminoanthraquinone; Disperse blue 1 CA Reg. No.: 2475-45-8 Source: Aldrich 2-Methylanthraquάnone CA Reg " . No.: 84-54-8 Source: Aldrich 9,10-Dihydro-9,10-dioxo-2,7-anthracenedisulfonic acid, di Na salt; Anthraquinone-2,7-disulfonic acid, di Na salt CA Reg. No.: 853-67-8 Source: K & K 1,2,3-trihydroxyanthraquinone; Anthragallol CA Reg. No. : 602-64-2 Source: K & K Carmine (Aluminum lake) CA Reg. No.: 1390-65-4 Source: Fisher Scientific Co., Inc. 711 Forbes Avenue Pittsburg, PA 15219 9,10-Dihydro-l,4-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid CA Reg. No. : 145-48-2 Source: Pfaltz & Bauer 2-Amino-3-chloroanthraquinone CA Reg. No.: 84-46-8 Source: Kodak 1-Anthraquinonesulfonic acid, Na salt CA Reg. No-; 128-56-3 Source: Kodak 2-tert-butylanthraquinone (98%) CA Reg. No. : 84-47-9 Source: Aldrich 1,4-Dihydroxyanthraquinone CA Reg. No. : 81-64-1 Source: Lancaster 1,5-Diamino-4,8-dihydroxyanthraquinone CA Reg. No.: 145-49-3 Source: Lancaster l-Hydroxy-4-[ (4-methylphenyl)amino]-9,10- anthracenedione; l-Hydroxy-4-(p-toluidino) anthraquinone CA Reg. No. : 81-48-1 Source: Sigma 1,4-Dimethylanthraquinone (95%) CA Reg. No.: 1519-36-4 Source: Pfaltz & Bauer 1,1'-Iminobis-9,10-anthracenedione; Dianthrimide CA Reg. No.: 82-22-4 Source: Pfaltz & Bauer 2-(Cyclopropylcarboxamido)anthraquinone CA Reg. No. : None Source: Aldrich l-Amino-2-methylanthraquinone; Disperse orange 11 CA Reg. No.: 82-28-0 Source: Sigma 2-[(9,10-Dihydro-4-hydroxy-9,10-dioxo-l- anthracenyl)amino]-5-methyl-benzenesulfonic acid, Na salt; Solway purple R CA Reg. No.: 4430-18-6 Source: K & K 2 , 2 ' - [ (9, 10-Dihydro-5, 8-dihydroxy-9, 10-dioxo-l, 4- anthracenediyl) diimino]bis [5-methyljbenzenesulfonic acid; alizarine viridine CA Reg . No . : 4430-16-4 Source : K & K 1,4-Bis(ethylamino)-9,10-anthracenedione; Sudan blue CA Reg. No.: 6994-46-3 Source: K & K 1,4-Diamino-5-nitroanthraquinone CA Reg. No. : 82-33-7 Source: K & K N-Benzyl-9, 10-dihydro-9, 10-dioxo-2-anthracenesulf onamide CA Reg . No . : None Source : Aldrich 2-Bromoanthraquinone CA Reg . No . : 572-83-8 Source: E. I. du Pont de Nemours and Company 1-Fluoroanthraquinone CA Reg. No. : 569-06-2 Source: E. I. du Pont de Nemours and Company 1-Cyanoanthraquinone pi !_____..-- xi- . • Λ O '-. e c "ai - Source: E. I. du Pont de Nemours and Company 2-Trifluoromethylanthraquinone CA Reg. No.: 362-21-0 Source: E. I. du Pont de Nemours and Company All the above-named compounds except N-[l-(9,10 dihydro-9,10 dioxo)anthracenyl]-N'-(1-methylethyl)imido dicarbonimidic diamide hydrochloride are commercially available. N-[l-(9,10 dihydro-9,10 dioxo)anthracenyl]- N'-(1-methylethyl)imido dicarbonimidic diamide hydrochloride, however, is a novel compound and was synthesized as follows: A three liter round bottomed flask was charged with 18.2 g (3.09 mole) of isopropyl amine. After cooling the flask to -70°C in a dry ice and acetone bath, 304.5 g of concentrated (37%) hydrochloric acid (3.09 mole) was added. The mixture was warmed to room temperature and water was removed with a rotary evaporator at aspirator pressure. To the dry residue was added 275.3 g (3.09 mole) of sodium dicyanamide and 760 ml of 1-butanol. The mixture was heated under reflux for three hours and then the butanol was removed with a rotary evaporator at aspirator pressure. To the residue in the flask was added 1800 ml of 1,4-dioxane. A slightly sticky precipitate was formed which was filtered and recrystallized from four liters of 1,4-dioxane to yield 379 g of N-cyano-N 1 - isopropylguanidine as a co-precipitate with some NaCl, 1,4-dioxane, and isopropylamine. Calc. for C5H 10 N 4 (NaCl)0.1(C 4 H 8 θ2)0.1(C3H 9 N)0.15 Calc: C 46.94; H 8.18; N 38.83; Cl 2.37 Found: C 46.85; H 8.27; N 38.42; Cl 2.44 To 5.02 g of 1-aminoanthraquinone (0.0225 mole) was added 2.22 g (0.0225 mole) of concentrated (37%) hydrochloric acid. The mixture was dried at 95°C on a rotary evaporator to give a free-flowing powder. Then. 20 ml of 1-butanol and 4.26 g of N-cyano-N 1 - isopropylguanidine as prepared above were added to the flask and the mixture was refluxed for one hour. The mixture was then cooled to room temperature (about 22°C) . The reaction was judged to be complete due to the absence of a cyano group infrared stretching frequency at 2180 cm" 1 . The product was precipitated by adding 100 ml of dietlϊyl ether and air dried to give 5.86 g of N-[l-(9,10 dihydro-9,10 dioxo)anthracenyl]-N'- (1-methylethyl)imido dicarbonimidic diamide hydrochloride having characteristic infrared absorption at 1640, 1601, 1540, and 1285 cm" 1 . The preferred anthraquinones to inhibit sulfide production by sulfate-producing bacteria are: 1,8- dihydroxyanthraquinone, 1-chloroanthraquinone, 2- chloroanthraquinone, and 3-chloro-2-anthraquinone carboxylic acid. If sulfate-reducing bacteria are growing by sulfate respiration (which is the growth mode from which they derive the most energy or growth) then inhibition of sulfide production will result in cessation of bacterial growth. Cessation of bacterial growth under these conditions may not necessarily result in cell death and does not preclude the bacteria utilizing other energy yielding pathways which do not involve sulfate as an electron acceptor as previously discussed. A number of different sulfate-reducing bacteria as well as several other organisms are suitable for use in the present invention and were used in the experiments of this invention. They were all grown in BTZ-3, BTZ-3 supplemented with other chemicals, or BTZ-4 medium. • These media will be described hereinafter. The organisms used in the experiments were obtained from the sources shown below but they are available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852. For use in the experiments below, Desulfovibrio desulfuricans G100A was isolated at E. I. du Pont de Nemours and Company, Wilmington, DE; £. desulfuricans API was obtained from the American Petroleum Institute; £. salexigens. £. vulςraris. £. desulfuricans 27774 and £. desulfuricans Norway were obtained from the laboratory of Dr. H.D. Peck Jr. University of Georgia, Athens GA 30601 and were grown in BTZ-3 medium supplemented with sterile sodium lactate (60 mM) and sodium sulfate (30 mM) . The β. salexiσens and β. desulfuricans Norway strains were grown in BTZ-3 medium supplemented additionally with sodium chloride to a final concentration of 0.4 M. BTZ-3 medium was used to grow Escherichia £&li and 2. denitrϊfj ns, however, the medium was then supplemented differently for each organism to contain 5 mM glucose for £. coli and 25 mM sodium thiosulfate and 10 mM sodium nitrate for 1. denitrificans. Growth conditions for all the above organisms were strictly anaerobic with a nitrogen atmosphere. Where reducing agents were added to the medium a reducing agent of the following composition was used: Sodium sulfide 9 hydrate 50 mM Cysteine hydrochloride 50 mM in 0.1 N sodium hydroxide There may be a problem in delivering a known amount of an anthraquinone to an aqueous system because these compounds are not very soluble in water. Therefore solvent systems to deliver concentrated amounts of inhibitor accurately may be required. Suitable solvents for use herein comprise water-miscible solvents. Examples of such solvents include, but are not limited to, water, detergent emulsions in water, ethanol, acetone, methanol, dimethylsulfoxide, dimethylformamide, cr tetrahydrofuran. Due to their aqueous insolubility, one cannot be certain that the final concentration of the compound correlates, in a linear fashion, with the amount added in the organic solvent. The water solubility of, for example, the 1,8 dihydroxyanthraquinone is 2-3 ppm, however it is demonstrated that additions of the compound in excess of this amount have additional inhibitory effect, therefore it is often necessary and beneficial to add the inhibitor in excess of its theoretical solubility. Typically, in our experiments, the anthraquinone to be tested was dissolved to a concentration of 300 ppm in ethanol: ater (80:20, 20 mM pH7 sodium phosphate buffer) . This was used to deliver the compound to a growing bacterial suspension in BTZ-3 medium. While this is the preferred solvent, other solvents such as acetone, methanol-water (80:20), di ethylformamide, and tetrahydrofuran have proven to be equally efficacious. The pH of the ethanol-water system can be from 5 to 12 with no apparent pH effect. There is no reason to suspect that the compound must be delivered in the ethanol-water buffer or acetone or any particular organic solvent. In fact depending upon the particular system or anthraquinone, the solid compound could be added to it directly. Experiments have established that the compounds are effective at a final concentration of at least 0.1 ppm. When an inhibitory anthraquinone is added to a growing culture of Desulfovibrio sp. growth and sulfide formation cease immediately at anthraquinone concentrations of 3 ppm. This cessation typically lasts for several days after which growth resumes. This effect has been demonstrated with several different species of Desulfovibrjo in pure culture. It has also been found that the redox potential of the culture affects the potency of the anthraquinone. Compounds are most effective when added to a culture in early exponential growth where some sulfide has already been produced thus rendering the medium more reduced than uninoculated medium. However compounds still show some inhibition when added to oxidized medium which is subsequently inoculated. It has been shown that use of a reducing agent can enhance the strength of the inhibition even when the inhibitor is added concurrently with the inoculum. A preferred reducing agent is sodium sulfide at concentrations of between about 2 and about 4 mM in the medium. This aspect would suggest that the compounds are most effective under anaerobic, reduced conditions as would be found in, for example a sewage treatment anaerobic digestor, or in another respect the compounds may be thought of as being activated by the end-product of the sulfate-reducer which is sulfide. Another object of this invention is a process for the automated screening of inhibitors of sulfide production by bacteria. While any sulfide-producing bacterium can be used, an isolate of Desulfvibrio desulfuricans (strain G100 A) from an oilfield was used for the experiments described. The isolation and physiological characteristics of this strain have been described previously by Weimer et al., 1988 Appl. Environ. Microbiol. 54:386-396. The process comprises: a) maintaining a culture of sulfate-reducing bacteria in exponential growth phase by chemostat culture of the organsims; b) contacting in an automated analyzer a solution of the compound to be tested with an aliquot of said culture of step a); c) adding to the compound and culture a substrate to initiate sulfide production; d) incubating the culture, compound and substrate mixture to permit sulfide production; and e) measuring the amount of sulfide produced. The system is shown schematiclly in Fig 1. The candidate inhibitors are delivered from an automated sampler (1) into the bacterial culture stream (2) (The culture was freshly removed from the chemostat into a 158 ml serum vial and sparged with argon or nitrogen for about 1 hour to reduce the background sulfide level to below 0.2 mM) . Immediately, small bubbles of nitrogen gas (3) are introduced into the bacterial culture/inhibitor stream to produce discrete liquid segments. After traversing this and a ten-turn mixing coil (4) (time required is about 1.6 min), substrate solution (5) (10 mM Na lactate, 5 mM a 2 Sθ , and from 0.1% to 0.2% final concentration using a 30% stock solution of Brij 35® (v/v) (trademark of Atlas Chemical Industries, Inc. and available from Fisher Scientific Co., Fairlawn, NJ 07410)) is introduced into each liquid segment. The segments traverse the downstream tubing (6) in the system for about 18 minutes, at which point a small amount of 0.03N sulfuric acid (7) is added to reduce the pH to about 4.5. At this pH, sulfate reduction ceases and greater than 99% of the sulfide anions (S" and HS~) are converted to H 2 S without lysing the bacterial cells. The H 2 S diffuses through a gas- permeable silicone membrane (8) and is picked up by a very dilute solution of Brij 35® surfactant (9) , which aids in maintaining the integrity of the individual liquid segments. The sulfide is next reacted with N,N-dimethyl-p-phenylenediamine sulfate or dihydrochloride (DPD,10) and ferric chloride (11) to produce methylene blue whose concentration is determined by the spectrophotometric flow cell (12) at the end of the reaction loop. The letters A through D on Figure 1 indicate flow rates for polyvinylchloride pump tubing of the indicated collar color as follows: A = orange/green 0.10 ml/min.; B = orange/white 0.23 ml/min.; C = black/black 0.32 ml/min.; D = red/red 0.8 ml/min. Such tubing is available from Technicon Instruments Corp., Tarrytown, N.Y., as Flow Rated Pump Tube, from Precision Technology, Inc., 375 Oaktree Rd., Palisades, N.Y., 10964 as Acculab® Flow Rated Pump Tubes, and from Elkay Products via Fisher Scientific Co., Fairlawn, N.J., 07410 as AccuRated® pump tubing. Culture, inhibitor and substrate solutions are typically added at equivalent volumes. Typical reagent concentrations used are as follows: substrate « 1.12 g sodium lactate + 0.71 g Na2Sθ /L; DPD = N,N-dimethyl-p-phenylenediamine sulfate or dihydrochloride at 1.19 g/L in 1.14 N HCl; ferric chloride = 3.1 g/L in 1.14 N HCl; surfactant = 1.0 ml/L of 30% Brij 35®. The letter T represents the number of turns of glass mixing coils. All parts used were standard Technicon® AutoAnalyzer II® parts available from Technicon® Instruments Corporation, 511 Benedict Avenue, Tarrytown, NY 10591. Similar equipment which provides equivalent results can also be used. In order to maintain anaerobic conditions for the bacteria and to prevent oxidation of the sulfide generated during the incubation, the entire apparatus is contained inside an anaerobic glovebag (Coy Manufacturing Co., Ann Arbor, Michigan). However, sparging of the culture vessel is to be avoided, as it reduces the background level of sulfide in the culture and thus causes baseline drift. The net amount of sulfide produced is determined by subtracting the background amount of sulfide produced by combining fresh culture filtrate with lactate/sulfate and with water (instead of the inhibitor solution) , from the amount of sulfide produced by combining culture, lactate/sulfate, and water. The culture filtrate is obtained by filtering the sparged chemostat sample described above through a 0.2 μm filter; this filtration is performed in the glovebag to prevent oxidation of the sulfide. In order to provide a baseline measure of sulfide production by uninhibited cultures, a vial of N 2 ~sparged water is inserted between each candidate inhibitor vial in the autosampler rack. Sulfide production resulting from this combination of water, culture, and lactate/sulfate represents the amount of sulfide produced by the uninhibited culture. A typical chart trace from an AutoAnalyzer® run is shown in Fig. 2. A indicates the 0.45 mM sodium sulfide standard plus lactate/sulfate plus water. B is the culture filtrate plus lactate/sulfate plus water. C is the cell suspension plus lactate/sulfate plus water. The numbers 1 through 12 indicate different test compounds plus cell suspension with substrate. The points indicated by a dot above each downward-tending peak represent the level of sulfide in uninhibited cultures. Note that the inclusion of a water vial between each candidate inhibitor provides a convenient marker for determining the amount of inhibition obtained for each compound. The extent of inhibition of sulfate is calci-lated as follows: % inhibition ■= 1- net "^ sulfide in p resence of inhibitor χ QQ net mM sulfide in absence of inhibitor Because the automated assay is based upon the measurement of sulfide production, test compounds which react with sulfide (whether by oxidation, complexation, or precipitation) will underestimate the net amount of sulfide formed and thus overestimate the extent of inhibition. The detection of such reactivity can usually be accomplished by the assay method if the cell suspension used has a moderate background level of sulfide; reactive compounds will often yield a sulfide peak below that obtained from the filtrate itself (Fig. 2, peak 9) , particularly if the candidate inhibitor is tested at relatively high concentration. However, it is essential that all compounds which appear to cause a net decrease in sulfide formation be retested for their reactivity with sulfide in the absence of active cells. This is most easily accomplished by using an automated analyzer to combine test compound, lactate/sulfate, and (instead of a bacterial suspension) a standard solution (e.g., 0.5 mM) of sodium sulfide. Reaction with sulfide is detected as a decrease in methylene blue formation that is detected by the spectr©photometer. Under normal operating conditions, the instrument's recording chart is set such that full scale was equivalent to either 0.5 or 1.0 mM sulfide. A steady chart trace permits the detection of changes in sulfide production of 5 to 10 μM (0.01 X full scale absorbance) . The relative sensitivity could be enhanced even further by increasing the total amount of sulfide formed (e.g., by lengthening the reaction path) . The screen has been used to test a wide variety of compounds for their ability to inhibit bacterial sulfide production. It has also been used to evaluate promising inhibitors with respect to concentration effects and to retention or loss of inhibitory activity following exposure to environmental stresses (e.g., extremes of temperature or salinity) . The automated nature of the method permits unattended operation and maximizes sample throughput (particularly if a 144-sample automated sampler tray is used) while retaining the high degree of reproducibility afforded by the use of chemostat-grown cells. The method has been effective in rapidly identifying compounds which inhibit sulfide production by sulfate-reducing bacteria. The enhanced reproducibility of the assay method resulting from the use of chemostat-grown bacteria is in agreement with the report of Lagarde et al., 1976 Corrosion, Traitments, Protection, Finition 15: 275-280, who screened inhibitors by determining changes in bacterial cell density and sulfide production following direct addition of test compounds to chemostats containing sulfate- reducing bacteria. While their method provided reproducible data, it is not practical for screening large numbers of compounds, due to the limited mumber of chemostats that can be maintained simultaneously, and to the long time required to re-establish steady-state biological and chemical conditions following addition of inhibitor. The following Examples showing the results of the screening process (i.e., inhibition of sulfide production) and other aspects of the inhibition of sulfide production by anthraquinones illustrate the present invention but are not intended to limit it in any way. EXAMPLE 1 Screening Anthraquinones for Inhibition of Sulfide Production bv Desulfovibrio desulfuricans G100A: A culture of Desulfovibrio desulfuricans G100A was maintained in exponential growth phase by chemostat culture of the organism. The organism was maintained in a single stage chemostat (working volume » 1 liter) continuously fed BTZ-4 medium which is BTZ-3 medium modified to contain 40 mM sodium lactate as growth limiting nutrient, and a reduced (to 0.05 mM) level of ferrous iron. The medium designated BTZ-3 consisted of the following mineral base: Ammonium sulfate 5.3 g Potassium dihydrogen phosphate 0.68 g (or Dipotassium hydrogen phosphate 0.087 g) Magnesium sulfate heptahydrate 0.2 g Calcium chloride dihydrate 0.1 g 39 Mineral solution 10X, 1.0 ml. Iron sulfate heptahydrate 0.0042g Deionized water to a final volume of 1 liter Composition of 10X mineral solution: Nitrilotriacetic acid 12.8 g Cupric chloride 2H 2 O 0.254 g Manganese chloride 4H 2 O 1.0 g Cobalt chloride 6H2O 3.115 g Zinc chloride 1.0 g Boric acid 0.1 g Sodium olybdate 2H2O 0.1 g Nickel chloride 6H 2 O 1.84 g Deionized water to 1000 ml pH to 7.0 The chemostat was operated at ambient temperature (19 to 24 °C). pH 7.9 to 8.2, and a dilution rate of 0.035 per hour. Bacterial concentrations (as determined by direct counting in a Petroff-Hauser counting chamber and a phase contrast microscope) consistently fell between 7 and 9 x 10 8 cells per ml. The automated screen in this example used a Technicon® AutoAnalyzer® II as both an incubator to expose chemostat-grown bacteria to different inhibitors in the presence of bacterial growth substrates (lactate and sulfate) , and as an analyzer of the amount of H2S formed as a consequence of the incubation. Thus compounds were each tested with bacteria of the same strain at about the same bacterial cell density (i.e.,7-9 x 10 8 cells/ml) and the same stage of growth (exponential) . Compounds were prepared as 300 ppm solutions in ethanol:aqueous:phosphate buffer (80:20, 20 mM Phosphate pH 7) . After solubilizing the compound in this solution, the solution was diluted 10 fold and an aliquot placed in the AutoAnalyzer®. Introduction of the aliquot of compound into the bacterial suspension resulted in another 3 fold dilution and thus compounds were actually exposed to the cells at 10 ppm (theoretical) concentration with 2.7% ethanol and 0.7 mM phosphate present. Controls with solvent only (minus compound to be tested) were run for each compound tested. An additional control used was chlorhexidine, a potent non-specific bacteriocide which also inhibits sulfide production. Inhibition by this compound was an indicator of the overall reproducibility of the assay and results were expressed both as total percent inhibition of sulfide production and inhibition relative to chlorhexidine inhibtion. In the AutoAnalyzer® compounds were mixed with the bacterial suspension and incubated for approximately 1.6 minutes at which time the substrates for sulfide production were added (10 mM sodium lactate and 5 mM sodium sulfate) . This mixture was then incubated for an additional 18 minutes to allow the formation of sulfide. The reaction was stopped by volatilizing the formed sulfide with a small amount of sulfuric acid and measuring the formed sulfide as described in detail above. The resulting data are summarized in Table I. In Table I, the notation "<10 ppm" indicates that the compound was not totally soluble upon visual inspection of the sampling vials at a concentration of 30 ppm in 8% EtOH prior to the 3x dilution by the analyzer. The notation "«10 ppm" indicates that there was very little solubility upon visual inspection of the sampling vials at a concentration of 30 ppm in 8% EtOH prior to the 3x dilution by the analyzer. Table i Compound: N-[1-(9,10-dihydro-9,10-dioxo)anthracenyl]-N'-(1- methylethyDimidodicarboniroidic diamide hydrochloride % Inhib. 83.1% (10μM-3% EtOH,) Compound: 1-Aminoanthraquinone (97%) % Inhib. 28.4% θ lOppm in 2.7% EtOH Compound: 2-Aminoanthraquinone % Inhib. 30.4% G lOppm in 2.7% EtOH Compound: 1-Amino-4-hydroxyanthraquinone % Inhib. 54.3% 6 <10ppm in 2.7% EtOH Compound: 1,2-Diaminoanthraquinone % Inhib. 28.9% G lOppm in 2.7% EtOH Compound: 2, 6-Dihydroxyanthraquinone; Anthraflavic acid % Inhib. 28.2% G lOppm in 2.7% EtOH Compound: Anthraquinone-2-carboxylic acid (98%) % Inhib. 22.6% G <10ppm Compound: 1,5-Dihydroxyanthraquinone; Anthrarufin (92%) % Inhib. 31.0% G lOppm in 2.7% EtOH Compound: 1,2-Dihydroxyanthraquinone; Alizarin % Inhib. 68.9% G lOppm, in 2.7% EtOH Compound: 2,2'-[ (9,10-Dihydro-9,10-dioxo-l,5-anthracenediyl) dii ino]bis[5-methylbenzenesulfonic acid], di Na salt; Alizarin violet 3R % Inhib. 30.9% G lOppm Compound: 1,2,5,8-Tetrahydroxyanthraquinone; Quinalizarin % Inhib. 80% β lOppm in 2.7% EtOH Compound: 4-Amino-9,10-dihydro-l,3-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid, monosodium salt; Nuclear fast red % Inhib. 20.4% θ lOppm Compound: 1,8-Dihydroxyanthraquinone; Danthron % Inhib. 82.2% G 10 ppm in 2.7% EtOH Compound: 2,2 » -[ (9,10-Dihydro-9,10-dioxo-l,4- anthracenediyl)diimino]bis[5-methylbenzenesulfonic acid],di Na salt; Acid green 25 % Inhib. 38.8% θ lOppm Compound: l-Amino-2, -dibromoanthraquinone % Inhib. 44.6% G lOppm in 2.7% EtOH Compound: 5-Chloro-l-aminoanthraquinone % Inhib. 57.1% G lOppm in 2.7% EtOH Compound: 2-Ethylanthraquinone (97+%) % Inhib. 57.1% G approx. lOppm in 2.7% EtOH Compound: 1-Hydroxyanthraquinone (97%) % Inhib. 59.3% ' lOppm in 2.7% EtOH Compound: 2-(Hydroxymethyl)anthraquinone (97%) % Inhib. 87% G <10ppm in 2.7% EtOH Compound: l-Amino-4-methoxyanthraquinone % Inhib, 57.1% R lOppm in 2.7% EtOH 43 Compound: l-Amino-6,7-dichloroanthraquinone % Inhib. 22.9% fi <10ppm in 2.7% EtOH Compound: Benz[a]anthracene-7,12-dione (97%) % Inhib. 52.9% θ <10ppm in 2.7% EtOH Compound: 1,8-Dihydroxy-3-methylanthraquinone; Chrysophanic acid % Inhib. 27.9% G <10ppm in 2.7% EtOH Compound: 10-[ (3-Amino-2,3,6-trideoxy-alpha-L-lyxo- hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6, 8,11- trihydroxy-8-(hydroxyacetyl)-l-methoxy-5,12- naphthacenedione hydrochloride; Adriamycin hydrochloride % Inhib. 55.7% θ <10ppm in 2.7% EtOH Compound: 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2- anthracenecarboxylic acid; Rhein % Inhib. 48.6% G <10ppm in 2.7% EtOH Compound: (8S-cis)-8-Acetyl-10[ (3-amino-2,3,6-trideoxy- alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10- tetrahydro-6,8,ll-trihydroxy-l-methoxy-5,12- naphthacenedione hydrochloride; Daunomycin hydrochloride % Inhib. 62.9% G <10ppm in 2.7% EtOH Compound: 1,2,4-Trihydroxyanthraquinone; Purpurin % Inhib. 55.7% θ <10ppm in 2.7% EtOH Compound: 1-Aminoanthraquinone diazonium salt % Inhib. 20.8% 6 <10ppm in 2.7% EtOH Compound: 2 2'-Dimethyl-[1,1*-bianthracene]-9,9',10,10'-tetrone; 2,2'-Dimethyl-1,1*-bianthraquinone % Inhib. 59.7% θ <10ppm in 2.7% EtOH Compound: 3-(D-apio-beta-D-Furanosyloxy)-1,8-dihydroxy-6-methyl- 9,10-anthracenedione; Frangulin B % Inhib. 57.1% θ <10ppm in 2.7% EtOH Compound: 2-Chloroanthraquinone (99%) % Inhib. 98.7% θ «10ppm in 2.7% EtOH Compound: 1,5-Dichloroanthraquinone (96%) % Inhib. 100% θ «10ppm in 2.7% EtOH Compound: 1,4,5,8-Tetrachloroanthraquinone % Inhib. 50.6% G «10pρm in 2.7% EtOH Compound: 1-Chloroanthraquinone % Inhib. 20.8% θ <10ppm in 2.7% EtOH Compound: 1,8-Dichloroanthraquinone (97%) % Inhib. 3.9% θ <10ρpm in 2.7% EtOH Compound: 2-Bromo-3-methylanthraquinone % Inhib. 26.0% G «10ρpm in 2.7% EtOH Compound: 2-(2,2,2-Trimethylpropionamido)anthraquinone % Inhib. 48.1% θ <10ppm in 2.7% EtOH Compound: 2,6-Bis[2-(dimethylamino)ethoxy]-9,10-anthracenedione; Tilorone analog R11,043DA % Inhib. 98.7% G lOppm in 2.7% EtOH Compound: 2-Methyl-1-nitroanthraquinone % Inhib. 50% G «10ppm in 2.7% EtOH Compound: l-Amino-9,lO-dihydro-9,10-dioxo-2-anthracenesulfonic acid; l-Aminoanthraquinone-2-sulfonic acid % Inhib. 37.5% β <10ppm in 2.7% EtOH Compound: 9,10-Dihydro-5-nitro-9,10-dioxo-l-anthracenesulfonic acid; 5-Nitroanthraquinone-l-sulfonic acid % Inhib. 66% G lOppm in 2.7% EtOH Compound: 3-Chloro-9,10-dihydro-9,10-dioxo-2-anthracene- carboxylic acid; 2-Chloroanthraquinone-3-carboxylic acid % Inhib. 100% G lOppm in 2.7% EtOH Compound: 50/50 Mixture of Anthrarufin and Danthron CA Reg. No. : None % Inhib. 62.5% G 5ppm in 2.7% EtOH Compound: Anthraquinone % Inhib. 37.5% G lOppm in 2.7% EtOH Compound: 1, 8-Dihydroxy-3-(hydroxymethyl)-anthraquinone; Aloe- emodin % Inhib. 43.8% G lOppm in 2.7% EtOH Compound: 7,16-Dichloro-6,15-dihydro-5,9,14,18-anthrazine- tetrone; 7,16-Dichloroindanthrone % Inhib. 43.8% G lOppm in 2.7% EtOH Compound: 1,2,3,4,5, 8-Hexahydroxyanthraquinone; Alizarin cyanin % Inhib. 40.6% θ lOppm in 2.7% EtOH Compound: 2,4,5,7-Tetrabromo-l,8-dihydroxy-9,10-anthracenedione; 2,4,5,7-Tetrabromochrysazin % Inhib. 40.6% G lOppm in 2.7% EtOH Compound: 1,2,7-Trihydroxyanthraquinone; Anthrapurpurin % Inhib. 37.5% G lOppm in 2.7% EtOH Compound: 1, ,5-Trihydroxy-2-methyl-9,10-anthracenedione; Islandicin % Inhib. 50% G lOppm in 2.7% EtOH Compound: 1,4,5,7-Tetrahydroxy-2-methyl-9,10-anthracenedione; Catenarin % Inhib. 37.5% θ lOppm in 2.7% EtOH Compound: 1,8-Dihydroxy-3-methoxy-6-methyl-9,10-anthracenedione; Physcion % Inhib. 34.4% G lOppm in 2.7% EtOH Compound: 1,4,5,8-Tetrahydroxy-2-methyl-9,10-anthracenedione; Cynodontin % Inhib. 34.4% G lOppm in 2.7% EtOH Compound: 1,5, 8-Trihydroxy-3-methyl-9,10-anthracenedione; Helminthosporin % Inhib. 31.3% G lOppm in 2.7% EtOH Compound: l-Hydroxy-2-[ (6-O-β-D-xylopyranosyl-β-D- glucopyranosyl)oxy]-9,10-anthracenedione; Ruberythric acid % Inhib. 29.7% θ lOppm in 2.7% EtOH Compound: 2-Phenoxy quinizarin-3, '-disulfonic acid, di K salt % Inhib. 28.1% G lOppm in 2.7% EtOH Compound: {+,-)-l-Acetoxy-8-hydroxy-l, ,4a,9a- tetrahydroanthraquinone % Inhib. 28.1% G lOppm in 2.7% EtOH Compound: l-Amino-4[[4-[ (dimethylamino) ethyl]phenyl)- amino-9,10-anthracenedione; Basic Blue 47 % Inhib. 37.2% θ lOppm in 2.7% EtOH Compound: 1,5-Bis(2-carboxyanilino)-9,10-anthracenedione; Acridylic acid % Inhib. 33.5% G lOppmin 2.7% EtOH Compound: 1,8-Dihydroxy-9-anthranol; 1,8-Dihydroxyanthranol % Inhib. 88.3% θ <10ppm in 2.7% EtOH Compound: 1,2,10-Anthracenetriol; Anthrarobin % Inhib. 44.4% G lOppm in 2.7% EtOH Compound: l-Amino-4-bromo-2-methylanthraquinone (99%) % Inhib. 8% θ <10pρm Compound: 1,4-Diaminoanthraquinone (97%) % Inhib. 27.5% G lOppm in 2.7% EtOH Compound: 2, 6-Diaminoanthraquinone % Inhib. 27.2% G lOppm in 2.7% EtOH Compound: l-Amino-4[4-[[4-chloro-6[[2,3 or 4-sulfoρhenyl]amino]■ 1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10- dihyro-9,10-dioxo-2-anthracenesulfonic acid; Procion blue HB(S); Reactive blue 2; Cibacron blue 3G-A; Basilen blue E-3G % Inhib. 17.5% G lOppm Compound: Anthraquinone-1,5-disulfonic acid di Na salt hydrate (95%) % Inhib. 17.5 % θ lOppm Compound: Anthraquinone-2,6-disulfonic acid di Na salt % Inhib. 9.8% θ lOppm Compound: Anthraquinone-2-sulfonic acid sodium salt monohydrate % Inhib. 17% θ lOppm Compound: 1,2-Bis[ (4-sulfophenyl)amino]-4-hydroxy-anthraquinone; Alizarin blue black B % Inhib. 17.5% G lOppm Compound: (3,4-dihydroxy-2-anthraquinonyl)-methyliminodiacetic acid; 3-aminomethylizarin-N,N-diacetic acid; Alizarin complexone dihydrate % Inhib. 14.3% θ <10ppm in 2.7% EtOH CCompound: l-Amino-4-[[3-(ethenylsulfonyl)phenyl]-9,10-dihydro- 9,10-dioxo]-2-anthracene sulfonic acid, monosodium salt; Acid blue 215 % Inhib. 19.7% G lOppm Compound: 1-(Methylamino)anthraquinone (98%) % Inhib. 19.1% G <10ppm. Compound: 2,2*-[(9,10-Dihydro-5,8-dihydroxy-9,10-dioxo-l,4- anthracendiyl)diiminojbis[5-methylbenzenesulfonic acid] , di Na salt; Acid green 41 % Inhib. 17.8% G lOppm Compound: 2,2'-[ (9,10-Dihydro-9,10-dioxo-l,4-anthracenediyl)- diimino]bis[5-butylbenzenesulfonic acid]; Acid green 27 % Inhib. 16.5% G lOppm 49 Compound: 1,1'-Iminobis[4-amino] ,10-anthracenedione, sulfonated; Acid black 48 % Inhib. 13.8% fi lOppm Compound: l-Amino-9,lO-dihydro-9,10-dioxo-4-(phenylamino)-2- anthracenesulfonic acid, Na salt; Acid blue 25 % Inhib. 26% G lOppm in 2.7% EtOH Compound: 4-[[4-(Acetylamino)phenyl]amino]-l-amino-9,10-dihydro- 9,10-dioxo-2-anthracenesulfonic acid, Na salt; Acid blue 40 % Inhib. 12.5% θ lOppm Compound: l-Amino-9,10-dihydro-9,10-dioxo-4-[[3[[2-(sulfoxy) ethyl]sulfonyl]phenyl]amino]-2-anthracenesulfonic acid, disodium salt; Remazol Brilliant blue R; % Inhib. 12.4% G lOppm Compound: l-Amino-4[ [3-[4, 6-dichloro-l,3,5-triazin-2-yl)amino] 4-sulfophenyl]amino]-9,10 dihydro-9,10-dioxo-2- anthracenesulfonic acid; reactive blue 4; % Inhib. 7.3% G lOppm Compound: l-(9,10-Dihydro-9,10-dioxo-l-anthracenyl-l,2- hydrazinedisulfonic acid, di Na salt; (1- Anthraquinonyl)-1,2-hydrazine disulfonic acid, di Na salt % Inhib. 10% G lOppm in 2.7% EtOH Compound: 9,10-Dihydro-5,6-dihydroxy-9,10-dioxo-l- anthracenesulfonic acid; Alizarin-5-sulfonic acid % Inhib. 7.1% θ <10ppm in 2.7% EtOH Compound: N- (4-Chloro-9, lO-dihydro-9.10-dioxo-l- anthracenyl)benzamide; l-Benzaraido-4-chloro- anthraquinone % Inhib. 8.6% θ <10ppm in 2.7% EtOH Compound: l-Amino-4-bromo-9,10-dihydro-9,10-dioxo-2- anthracenesulfonic acid, Na salt; l-Amino-4- bromoanthraquinone-2-sulfonic acid, Na salt % Inhib. 4.3% G lOppm in 2.7% EtOH Compound: l-Amino-9,lO-dihydro-4[[ (4-methylphenyl)- sulfonyl]amino]-9,10-dioxo-2-anthracenesulfonic acid, Na salt; l-Amino-4-(p-toluenesulfonamido)- anthraquinone-2-sulfonic acid, Na salt % Inhib. 3.9% θ lOppm in 2.7% EtOH Compound: 9,10-Dihydro-9,10-dioxo-2,3-anthracenedicarboxylic acid % Inhib. 10% G <10ppm in 2.7% EtOH Compound: 1,1'-Iminobis(4-nitro-9,10-anthracenedione) % Inhib. 5.7% G <10ppm in 2.7% EtOH Compound: l-Amino-4-chloro-2-methylanthraquinone % Inhib. 5.2% θ <10ppm in 2.7% EtOH Compound: 2,3-dimethyl-l,4-dihydroxyanthraquinone; 2,3- Dimethylquinizarin % Inhib. 5.7% θ <10ppm in 2.7% EtOH Compound: 6-Methyl-l,3,8-trihydroxyanthraquinone; Emodin 99% % Inhib. 2.6% θ <10ppm in 2.7% EtOH Compound: 1,4-Bis(methylamino)-anthraquinone % Inhib. 8.6% θ <10ppm in 2.7% EtOH Compound: N-(4-Amino-9,10-dihydro-3-methoxy-9,10-dioxo-l- anthracenyl)-4-methylbenzenesulfonamide; N-(4-A ino- 3-methoxyanthraquinone-l-yl)-p-toluenesulfonamide; l-Amino-2-methoxy-4-(p-tolylsufonamido)anthraquinone % Inhib. 4.3% θ <10ppm in 2.7% EtOH Compound: [1,1'-Bianthracene]-9,9'10,10'-tetrone; 1,1'- Bianthraquinone % Inhib. 12.9% G <10ppm in 2.7% EtOH Compound: 6,7-Dichloro-l,4-dihydroxyanthraquinone 97% % Inhib. 5.7% G <10ppm in 2.7% EtOH Compound: 2-[ [9,10-Dihydro-4-(methylamino)-9,10-dioxo-l- anthracenyl]amino]-5-methyl-benzenesulfonic acid, monosodium salt; Alizarine astrol B-CF % Inhib. 2.6% G lOppm in 2.7% EtOH Compound: 2,8-Diphenyl-anthra[2,l-d:6,5-d']bisthiazole-6,12- dione; Indanthrene yellow GCN % Inhib. 15.6% θ lOppm in 2.7% EtOH Compound: 2-Methoxy-3-methyl-9,lO-anthracenedione % Inhib. 5.0% θ <10ppm in 2.7% EtOH Compound: 1,4-Bis[ (1-methylethyl) mino]-9,10-anthracenedione; 1,4-Di (isopropylamino)anthraquinone % Inhib. 5.0% θ <10ppm in 2.7% EtOH Compound: 1,4-Bis[ (2,4, 6-triethylphenyl)amino]-9,10- anthracenedione; 1,4-Bis(2,4, 6-triethyl- anilino)anthraquinone % Inhib. 4.3% θ <10ppm in 2.7% EtOH 52 Compound: 1-(2-Hydroxyethyl)amino-4-jnethylaminoanthraquinone; Disperse blue 3 % Inhib. 6.4% θ <10ppm in 2.7% EtOH Compound: 1,4-Bis[ (4-methylphenyl)amino]9,10-anthracenedione; Solvent green 3 % Inhib. 4.3% G <10ppm in 2.7% EtOH Compound: 2-Amino-3-hydroxyanthraquinone % Inhib. 11.4% θ <10ppm in 2.7% EtOH Compound: 1-(Bromothio)anthraquinone % Inhib. 6.5% G <10ppm in 2.7% EtOH Compound: 1,8-Bis(phenylmethoxy)-9,10-anthracenedione; 1,8- Dibenzyloxyanthraquinone % Inhib. 4.5% θ <10ppm in 2.7% EtOH Compound: l-Amino-2-(2-aminoethylthio)-4-hydroxyanthraquinone % ϊnhi'b 24.7% θ <10ρpm in 2.7% EtOH Compound: 1,4-Bis(pentylamino)-9,10-anthracenedione; Oil blue N % Inhib. 3.6% θ <10ppm in 2.7% EtOH Compound: 1-Amino-2-bromo-4-hydroxyanthraquinone % Inhib. 6.5% θ <10ppm in 2.7% EtOH Compound: 2-Propionamidoanthraquinone % Inhib. 10.4% θ <10ppm in 2.7% EtOH Compound: 1,4-Diamino-2,3-bis(2-phenoxyethoxy)anthraquinone % Inhib. 7.8% θ <10ppm in 2.7% EtOH Coimpound: N-(5-Chloro-9,10-dihydro-9,10-dioxo-l- anthracenyl) enzamide; l-Benzamido-5- chloroanthraquinone % Inhib. 10.4% 6 <10ppm in 2.7% EtOH Compound: Anthraquinone-1-arsonic Acid % Inhib. 18.2% G <10ppm in 2.7% EtOH Compound: N,N'-[Iminobis(9,10-dihydro-9,10-dioxo-4,1- anthracenediyl) ]bisbenzamide; 4,4'-Dibenzamido-1,1 dianthrimide % Inhib. 5.2% G <10ppm in 2.7% EtOH Compound: 1,4,5,8-Tetraaminoanthraquinone; Disperse blue 1 % Inhib. 3.9% θ <10ppm in 2.7% EtOH Compound: 2-Methylanthraquinone % Inhib. 10.4% θ <10ppm in 2.7% EtOH Compound: 9,10-Dihydro-9,10-dioxo-2,7-anthracenedisulfcnic acid, di Na salt; Anthraquinone-2,7-disulfonic acid, di Na salt % Inhib. 9.1% G <10ppm 2.7% EtOH Compound: 1,2,3-trihydroxyanthraquinone; Anthragallol % Inhib. 2.6% θ <10ppm in 2.7% EtOH Compound: Carmine (Aluminum lake) % Inhib. 7.8% G <10ppm in 2.7% EtOH Compound: 9,10-Dihydro-l,4-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid % Inhib. 7.8% θ <10ppm in 2.7% EtOH Compound: 2-Amino-3-chloroanthraquinone % Inhib. 3.9% θ <10ppm in 2.7% EtOH Compound: 1-Anthraquinonesulfσnic acid, Na salt % Inhib. 3.9% θ <10ppm in 2.7% EtOH Compound: 2-tert-butylanthraquinone (98%) % Inhib. 5.2% θ <10ppm in 2.7% EtOH Compound: 1,4-Dihydroxyanthraquinone % Inhib. 5.2% θ <10ppm in 2.7% EtOH Compound: 1,5-Diamino-4,8-dihydroxyanthraquinone % Inhib. 2.6% G <10ppm in 2.7% EtOH Compound: l-Hydroxy-4-[ (4-methylρhenyl)amino]-9,10- anthracenedione; l-Hydroxy-4-(p-toluidino)- anthraquinone % Inhib. 3.9% G <10ppm in 2.7% EtOH Compound: 1,4-Dimethylanthraquinone (95%) % Inhib. 5.2% G <10ppm in 2.7% EtOH Compound: 1,1'-Iminobis-9,10-anthracenedione; Dianthrimide % Inhib. 2.6% G <10pρm in 2.7% EtOH Compound: 2-(Cyclopropylcarboxamido)anthraquinone % Inhib. 2.6% θ <10ppm in 2.7% EtOH Compound: l-Amino-2-methylanthraquinone; Disperse orange 11 % Inhib. 5.2% G <10ppm in 2.7% EtOH 55 Compound: 2-[ (9,10-Dihydro-4-hydroxy-9,10-dioxo-l- anthracenyl)amino]-5-methyl-benzenesulfonic acid, Na salt; Sol ay purple R % Inhib. 9.1% θ <10ppm in 2.7% EtOH Compound: 2,2'-[ (9,10-Dihydro-5,8-dihydroxy-9,10-dioxo-l,4- anthracenediyl)diimino]bis[5-methyl]benzenesulfonic acid; alizarine viridine % Inhib. 2.6% G <10ρpm in 2.7% EtOH Compound: 1,4-Bis(ethylamino)-9,10-anthracenedione; Sudan blue % Inhib. 1.3% θ <10ppm in 2.7% EtOH Compound: 1,4-Diamino-5-nitroanthraquinone % Inhib. 2.7-3% θ <10pρm in 2.7% EtOH Compound: N-Benzyl-9,10-dihydro-9,10-dioxo-2-anthracene- sulfonamide % Inhib. 3.9% G <10ppm in 2.7% EtOH EXAMPLE 2 Anthraquinones which do not inhibit sulfide production The compounds listed in Table II were tested for inhibition of sulfide production as in Example 1 and were found not to be effective inhibitors . The notation "<10 ppm" is as previously defined in Example 1 . Tab] f? II Compound: 3, 4-Dihydroxy-9, 10-dioxo-2-anthracenesulfonic acid; Alizarin red S monohydrate CA Reg. No. : 130-22-3 % Inhib. 0 G lOppm Source : Aldrich 56 Compoun : 4-[[4-(Acetylmethylamino)phenyl]amino]-l-amino-9,10- dihydro-9,10-dioxo-2-anthracenesulfonic acid, Na salt; Acid blue 41 CA Reg. No. 2666-17-3 % Inhib. 0 G lOppm Source: Aldrich Compound: 4,8-Diamino-9,10-dihydro-l,5-dihydroxy-9,10-dioxo- 2,6-anthracenedisulfonic acid, di Na salt; Acid blue 45 CA Reg. No.: 2861-02-1 % Inhib. 0 G lOppm Source: Aldrich Compound: 3,3'-[ (9,10-Dihydro-9,10-dioxo-l, -anthracenediyl) adiimino]bis[2,4, 6-trimethylbenzenesulfonicacid] , di Na salt; Acid blue 80 CA Reg. No.: 4474-24-2 % Inhib. 0 G lOppm Source: Aldrich Compound: 7- β -D-Glucopyranosyl-9,10-dihydro-3,5,6,8- tetrahydroxy-l-methyl-9,10-dioxo-2- anthracenecarboxylic acid; Carminic acid CA Reg. No. 1260-17-9 % Inhib. 0 θ <10ppm Source: Aldrich Compound: l-Amino-4 [[3-[[4-chloro-6-[(3-sulfophenyl)amino]- 1,3,5-triazin-2-yl]amino]-4-sulfophenyl]amino]-9,10- dihydro-9,10-dioxo-2-anthracenesulfonic acid; Reactive blue 5 CA Reg. No.: 16823-51-1 % Inhib. 0 G lOppm Source: Sigma 57 Compound: N-(4-Amino-9,10-dihydro-9,10-dioxo-l-anthracenyl) benzamide; l-Amino-4-benzamidoanthraquinone CA Reg. No.: 81-46-9 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: Aldrich Compound: l-Amino-4-(methylamino)anthraquinone CA Reg. No.: 1220-94-6 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: Pfaltz £ Bauer Compound: 5-hydroxy-l,4-bis[(4-methylphenyl)amino]-9,10- anthracenedione; Sudan green CA Reg. No.: 4392-68-1 % Inhib. 0 G <10ppm in 2.7% EtOH Source: Pfaltz & Bauer Compound: l-Bromo-4-(methylamino)anthraquinone CA Reg. No. : 128-93-8 --:-,- — % Inhib. 0 G <10ppm in 2.7% EtOH Source: Kodak Compound: l,4-Diamino-2-methoxyanthraquinone; Disperse red 11 CA Reg. No.: 2872-48-2 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: Sigma Compound: Indanthrene black (suspension or liquid) ; C.I. Vat green 9 CA Reg. No.: 6369-65-9 % Inhib. -6.5% θ <10ppm/8% EtOH Source: Pfaltz £ Bauer 58 Compound: N, '- (9, 10-Dihydro-9,10-dioxo-l, 5-anthracenediyl) ' bisbenzamide; 1,5-Dibenzamidoanthraquinone CA Reg. No.: 82-18-8 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: K £ K Compound: Alizarin blue black BC CA Reg. No. : None % Inhib. 1.9% θ <10pρm in 2.7% EtOH Source: K £ K Compound: 9,10-Dihydro-3,4,6-trihydroxy-9,10-dioxo-2- anthracenesulfonic acid; Alizarin rubinol CA Reg. No.: 83631-51-0 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: K & K Compound: 9,10-Dihydro-l,3,4,5,7,8-hexahydroxy-9,10-dioxo-2, 6- anthracenedisulfonic acid; Acid alizarin blue BB CA Reg. No.: 83631-52-1 % Inhib. 0 G <10ppm in 2.7% EtOH Source: K £ K Compound: N,N'-[Iminobis (9,10-dihydro-9,10-dioxo-5,l- anthracenediyl)]bisbenzamide; 4,5'-Dibenzamido-1,1' dianthrimide CA Reg. No. 129-28-2 % Inhib. 0 θ <10ppm in 2.7% EtOH Source: Aldrich Compound: 1,4,4a,9a-Tetrahydroanthraquinone CA Reg. No.: 56136-14-2 % Inhib. 0-7% G lOppm in 2.7% EtOH Source: Aldrich EXAMPLE 3 Inhibition of sulfide formation bv 1-amino-anthraσuinone These determinations were, carried out in the AutoAnalyzer® as described in Example 1. The resulting data is shown in Table III. TABLE III Compound % inhibition of sulfide formation Chlorhexidine 88.7 1-amino-anthraquinone biguanide 83 1-amino anthraquinone 72 The data show that the 1-amino-anthraquinone biguanide which was derived from a chlorhexidine derivative and 1 amino-anthraquinone, as well as 1- amino-anthraquinone itself, inhibited sulfide formation by Desulfovibrio desulfuricans G100A. EXAMPLE 4 Effect of 1,8-dihydroxyanthraquinone on growth of P. desulfuricans G100A Four 10 ml culture tubes of BTZ-3 medium as defined in Example 1 supplemented with sodium lactate (40 mM) and sodium sulfate (30 mM) and 0.5 ml of reducing agent were inoculated with 100 ul of a fully grown suspension of 12 . desulfuricans G100A. The culture was allowed to grow and the optical density at 660 nm was monitored until the cells entered into exponential growth (approx. 12-15 h, O.D. 660 *= 0.1-0.2). At this time 100 ul of a 300 ppm solution of 1,8 dihydroxyanthraquinone, 1-chloranthraquinone or 3-chloro-2-anthraquinone carboxylic acid, respectively, was added to one of the tubes. The ethanol:water (80:20) solvent (100 μl) was added to the fourth tube to serve as an uninhibited 60 control. The resulting growth after the addition of the preferred inhibitors in comparison to the untreated control is shown in Table IV. TABLE TV Addition _t£ the Bacterial Cul ure* Hours of 1,8-dihydroxy- 1-chloro- 3-chloro-2-anthra- anthraquinone, anthraquinonβ quinone carboxylic acid .01 .01 .01 .12 .11 .10 .20 .12 .16 .19 .12 .21 .16 .27 .36 .16 .32 .38 .16 .32 .36 .18 .30 .37 .18 .32 .37 .30 .26 .34 .28 .23 .25 * optical density reading at 660 nm # 3 ppm inhibitor added at 12 hours. This example clearly shows that the addition of each of the three compounds to a final concentration of 3 ppm causes virtually complete cessation of growth of p. desulfuricans G100A for at least 80 hours. EXAMPLES 5-10 Effect of 1,8-dihydroxyanthraquinone on different species of sulfate-reducinσ bacteria Different species of sulfate-reducer were grown as described in Example 1 and then 250 μl of the grown suspension was inoculated into BTZ-3 medium containing reducing agent (1.0 ml/10 ml culture) and 1,8- dihydroxyanthraquinone at 3 ppm. Growth was monitored as optical density at 660 nm for 40 hours. The resulting data is shown in Table V. * no 1,8-dihydroxyanthraquinone present ** 1,8-dihydroxyanthraquinone present EXAMPLE 11 Effect of 1,8-dihydroxyanthraquinone on Thiobacillus denitrificans Thiobacillus denitrificans was grown on BTZ-3 medium as defined in Example 1 (supplemented with reducing agent) and with 30 mM sodium nitrate plus 30 mM sodium thiosulfate. Cultures were anaerobic under a nitrogen atmosphere. Thus growth conditions mimicked those for the sulfate-reducing bacteria as closely as possible. The 1,8-dihydroxyanthraquinone was added to the cultures at the indicated time and the growth monitored by observing the optical density at 660 nm. The results are shown below in Table VI. * Time of addition of 3 ppm of anthraquinone # Optical Density 6660 nm Significantly, the inhibitor had no effect on the growth of _«_ denitrifican^. This organism was chosen because its central metabolism involves sulfur compounds as is also the case with sulfate reducers. However, the Thiobacilli carry out the oxidation of sulfide rather than the reduction of sulfate, i.e., the reverse reaction of the sulfate reducers. EXAMPLE 12 Effect of 1.8-dihvdroxvanthracruinone on Escherichia coli Another non-sulfate reducing organism, Escherichia coli strain MC106 was grown under aerobic conditions on BTZ-3 with 30 mM sodium succinate as sole carbon and electron source with oxygen as electron accepter or under anaerobic conditions with hydrogen (80% as electron donor) and carbon dioxide (20%) as gas phase and sodium fumarate (30 mM) as electron acceptor. Both media contained 0.2% yeast extract. The resulting data are shown in Table VII. TABLE VII Aerobic growth with succinate Optical Density @ 660 nm Hours Control +5 ppm AQ* 0 0.01 0.01 5.5 0.17 0.24 6.5 0.37 0.39 7.5 0.38 0.40 24 1.50 1.50 Anaerobic growth under Hydrogen/carbon dioxide Hours Control +5 ppm AQ* 0 0.0 0.01 3.5 0.30 0.29 4.5 0.45 0.62 5.5 0.61 0.79 6.0 0.75 0.87 *1,8-dihydroxyanthraquinone Aerobic growth with succinate refers to growth on succinate as a carbon and electron source and oxygen as an electron acceptor. Anaerobic growth under hydrogen/carbon dioxide refers to growth with hydrogen as an electron donor and fumarate as an electron acceptor. Hydrogen consumption was observed in these cultures indicating that hydrogen v:as in fact used as an electron donor. 64 The data show virtually no inhibition of 1,8- dihydroxy-anthraquinone on the aerobic or anaerobic growth of E. coli. EXAMPLE 13 Effect on 1,8-dihydroxyanthraquinone on P. desulfuricans J- . desulfuricans strain G100A was grown using pyruvate fermentation in the absence of sulfate. The resulting data are shown in Table VIII. TABLE VIII * Time of addition of 3 ppm 1,8-dihydroxyanthraquinone. # Optical Density 6660 nm The anthraquinone did not affect fermentative growth of I . desulfuricans G100A. This shows that the inhibitory effects of anthraquinones are specific for sulfate reduction. Pyruvate fermentation does not involve the same enzyme systems utilized by the sulfate reduction pathway. EXAMPLE 14 Effect of 1,8-dihydroxyanthraquinone on sulfide production by crude enrichments from various naturallv-occurinσ environments All samples were grown on standard BTZ-3 medium (as defined in Example 1) under hydrogen (80%) carbon dioxide (20%) with 10 mM acetate and 0.1% yeast extract. Mud samples were inoculated into this medium and allowed to grow for 24 h to enrich for sulfate reducing bacteria. A 1 ml aliquot of this enrichment was transferred to fresh medium and the sulfide evolved was measured over a three day period. Sulfide was assayed as described by Siegal, Anal. Biochem. 11: 126-132, 1965, herein incorporated by reference. The resulting data are shown in Table IX. VS = Valley Stream State Park. Long Island, NY VF - Valley Garden Park, DE WCC = White Clay Creek Preserve, PA WADS *= Wilmington anaerobic digestor, DE SM-Lewes « Lewes saltmarsh, DE A = aerobic samples AN = anaerobic samples ♦Cultures contain 5 ppm 1,8-dihydroxyanthraquinone. The data shows that the majority of enrichments from natural sources were inhibited by the 1,8- dihydroxyanthraquinone. The cultures derived from the Wilmington anaerobic digestor or the Lewes saltmarsh were the least affected while the freshwater pond sediments showed the greatest inhibition. EXAMPLE 15 Effect of Anthraquinones on the Respiration Rate of P. desulfuricans 2777 The respiration rate (rate of hydrogen gas utlized) by °- ^ desulfuricans 27774 was measured with sulfate as the electron acceptor and hydrogen as the sole electron donor in the presence of each of three anthraquinones. The purpose was to show that respiration, an energy- yielding cellular reaction pathway, is sensitive to the anthraquinones, when sulfate is the electron acceptor used. Reaction mixtures had the following composition and the reactions were carried out in a Gilson respiromenter flask using standard manometric techniques. 200 ul of bacterial suspension (40 mg/ml protein of bacteria) 100 ul of 1 M phosphate buffer of pH 7 250 ul of 100 mM electron acceptor anthraquinone: 2 ul of 300ρpm soln (0.6 ppm final cone.) 10 ul of 300 ppm (3 ppm) 20 ul of 300 ppm (6ppm) DI water to 1.0 ml. The bacteria, water, buffer and inhibitor were incubated for 30 minutes under a 100% hydrogen atmosphere and then the electron acceptor was tipped into the main compartment and the reaction started. Gas uptake was measured over a period of 240 min and rates of gas uptake determined. The results are summarized below in Table X as percent of the rates of hydrogen gas uptake relative to those from mixtures incubated in the absence of anthraquinone. TABLE X Concen- Gas Uptake las percent of control) tration 1 Chloro- 1,8-Dihydroxy- 3-Chloro-2-anthra- (ppm) anthraquinone anthraquinone quinone carboxylic acid 0 100 100 100 .6 74 66 73 1.5 50 45 55 3 38 30 41 This experiment shows that at 3 ppm the three anthraquinone inhibitors gave a 59-70% inhibtion of control respiration rates. This both supports the result of Example 4 showing that 3 ppm inhibits bacterial growth and further demonstrates that the sulfate reduction process is directly affected. EXAMPLES 16-19 Effect of Anthraquinones on Respiration Rates of D. desulfuricans 27774 The following experiments show the effect of the 1,8-dihydroxy-anthraquinone on the rate of hydrogen 68 utilization by bacteria in the presence of different electron acceptors. The method used was identical to that of Example 10, and the results are summarized in Tables XI, XII, XIII and XIV. EXAMPLE 16 TABLE XI Sulfite as electron acceptor (no sulfate present) with and without 3 ppm anthraquinone EXAMPLE 17 TABLE XII Fumarate as electron acceptor (no sulfate present) with and without 3 ppm anthraquinone Minutes 0 10 25 40 55 70 EXAMPLE IB TABLE XIII Thiosulfate as electron acceptor (no sulfate present) with and without 3 ppm anthraquinone Hydroσen. μl Minutes Control +6ppm 1,8-dihydroxy- anthraquinone 0 0 0 11 38 33 21 90 73 31 144 118 41 204 176 EXAMPLE 19 TABLE XIV Sulfate as electron acceptor with and without 3 ppm anthraquinone Examples 11-34 show that the sulfate-reduction pathway is specifically affected. Alternate electron acceptors (i.e, sulfite, thiosulfate and fumarate. Examples 16-18) show comparable respiration rates with and without anthraquinone hence the anthraquinones exhibit specificity for sulfate reduction. EXAMPLE 20 Effect of reduced anthraquinones on growth of GIOOA and BTZ-3 +30 mM sodium lactate + 30 mM sodium sulfate Three anthraquinones, 1,8-dihydroxy-, 1-chloro-, and 3-chloro-2-carboxy- were prepared as 1 ml of 1000 ppm solutions in acetone for the first two compounds or water for the third. These solutions were then treated with 1 mg of the strong reducing agent, sodium dithionite. 50 ul of each solution (for a final culture concentration of 5 ppm) was used immediately to treat growing cultures of D. desulfuricans G100A in BTZ-3 medium as defined in Example 1. The compounds were added to the 10 ml cultures at 15 h of growth. The data show that 5 ppm of any o± the three preferred anthraquinones will inhibit the growth of JJL,. desulfuricans G100A even when pre-reduced by dithionite to the reduced form. EXAMPLE 21 Assay of sulfide inhibition by anthraquinones usinσ resting cells of D. gigas. Experiments in this example were carried out using resting cells of Desulfovibrio σiσas rather than growing cells as was the case for the autoanalyzer system employing the Desulfovibrio desulfuricans G100A strain. The reason for this was that the £. σiσas strain retained respiratory activity under resting cell conditions whereas the £. desulfuricans G100A strain did not. Thus the experiment examined a different organism, different test system, and a different physiological state for the phenomenon of anthraquinone inhibition of sulfide production by Desulfovibrio sp. Active compounds, as determined by the autoanalyzer, were evaluated in comparison with four additional compounds not evaluated in the autoanalyzer. The date confirmed the inhibitory properties of the 1,8-dihydroxy- anthraquinone, the 1-chloroanthraquinone and demonstrated the inhibitory effect of four new compounds not screened by the autoanalyzer method: the 2-bromo- anthraquinone (CA Reg. No. 572-83-8), 1-fluoroanthra- quinone (CA Reg. No. 569-06-2), 1-cyanoanthraquinone (CA Reg. No. 38366-32-4) and 2-trifluoromethylanthraquinone (CA Reg. No. 362-21-0) . 500 ml cultures of Desulfovihrir. σiσas were grown on standard BTZ-3 medium as previously described in Example 1 with 30 mM sodium lactate, 30 mM sodium sulfate and 30 mM sodium fumarate. The culture was harvested after 24 h of growth at 31°C by centrifugation at 8000 rp in a GSA Sorvall rotor for 20 minutes. The cell pellet was resuspended in 30 ml of incubation assay mixture of the following composition: 50 mM HEPES buffer pH 7 buffer, 2.5 mM sodium lactate, 2.5 mM sodium sulfate. This suspension was centrifuged again at 10,000 rpm in a Sorvall SS-34 rotor for 5 minutes. The resulting cell pellet was resuspended in 5 ml of incubation assay buffer. Cell densities were generally near lOelO cells/ml. The samples were assayed for production in the presence of anthraquinones. 200 ul of the cell suspension was added to 1.2 ml of incubation assay mixture in a 5 ml capacity test tube. The tube was gassed with hydrogen gas for 20 minutes then the anthraquinones were added as ethanolic solutions, the tubes were then gassed with hydrogen again for 5 minutes. The reaction mixtures were then incubated for 3 hours at 31°C. The reactions were stopped by the addition of 200 ul of IN sodium hydroxide. After 20 minutes the alkaline mixtures were centrifuged in a table top microfuge for 4 minutes at 14,000 rpm to remove cells and cell debris. The supernatant was then assayed for sulfide using the ferric chloride-DPD reagent system as described by Siegel et al.. Anal. Biochem., 11:126-132, 1965, herein incorporated by reference. The results are summarized in Table XVI. The halo-derivatives as well as the cyano and hydroxy compounds displayed inhibitory properties with 50% or more inhibition of sulfide production in the 0.1-0.5 ppm range.

Claims: CLAIMS What is claimed is: 1. A process for inhibiting sulfide production by sulfate-reducing bacteria comprising contacting the medium containing the sulfate-reducing bacteria with an anthraquinone compound which has an activity of at least 21 calculated according to formula (I) : 0 Activity - 28.1 + Σ (coeff.) (I) wherein Σ (coeff.) comprises the sum of the coefficient values for each individual coefficient Ri through Re 5 present in the anthraquinones represented by structure A: or the corresponding derivative of structure (A) . 5 2. A process for inhibiting sulfide production by sulfate-reducing bacteria comprising contacting the medium containing the sulfate-reducing bacteria with one or more of the following compounds: 30 N-[l-(9,10-dihydro-9,l0-dioxo)anthracenyl]-N'-(1- methylethyl)imidodicarbonimidic diamide hydrochloride CA Reg. No. : none 1-Aminoanthraquinone CA Reg. No. : 82-45-1 - a -- 2-Aminoanthraquinone CA Reg. No.: 117-79-3 l-Amino-4-hydroxyanthraquinone CA Reg. No.: 116-85-8 1,2-Diaminoanthraquinone CA Reg. No.: 1758-68-5 2,6-Dihydroxyanthraquinone; Anthraflavic acid CA Reg. No. : 84-60-6 Anthraquinone-2-carboxylic acid CA Reg. No. : 117-78-2 1,5-Dihydroxyanthraquinone; Anthrarufin CA Reg. No.: 117-12-4 1,2-Dihydroxyanthraquinone; Alizarin CA Reg. No.: 72-48-0 2,2'-[ (9,10-Dihydro-9,10-dioxo-l,5- anthracenediyl)diiminojbis[5-methylbenzenesulfonic acid], di Na salt; Alizarine violet 3R CA Reg. No.: 6408-63-5 1,2,5,8-Tetrahydroxyanthraquinone; Quinalizarin CA Reg. No. : 81-61-8 4-Amino-9, 10-dihydro-l,3-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid, monosodium salt; Nuclear fast red CA Reg. No.: 6409-77-4 1 , 8-Dihydroxyanthraquinone; Danthron CA Reg . No . : 117-10-2 2 , 2 ' - [ ( 9, 10-Dihydro-9, 10-dioxo-l, 4- anthracenediyl) diimino] bis [5-methylbenzenesulfonic acid] , di Na salt; Acid green 25 CA Reg . No . : 4403-90-1 l-Amino-2, 4 -dibromoant hraquinone CA Reg . No . : 81-49-2 5-Chloro-l-anthraquinonylamine CA Reg . No . : 117-11-3 2-Ethylanthraquinone CA Reg . No . : 84-51-5 1-Hydroxyanthraquinone 2-(Hydroxymethyl)anthraquinone CA Reg. No.: 17241-59-7 l-Amino-4-methoxyanthraquinone . CA Reg. No.: 116-83-6 l-Amino-6,7-dichloroanthraquinone CA Reg. No.: 5355-88-4 Benz[a]anthracene-7,12-dione CA Reg. No.: 2498-66-0 1,8-Dihydroxy-3-methylanthraquinone; Chrysophanic acid CA Reg. No. : 481-74-3 10-[ (3-Amino-2,3,6-trideoxy-alpha-L-lyxo- hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11- trihydroxy-8-(hydroxyacetyl)-l-methoxy-5,12- naphthacenedione hydrochloride; Adriamycin hydrochloride CA Reg. No.: 23214-92-8 9,10-Dihydro-4,5-dihydroxy-9,10-dioxo-2- anthracenecarboxylic acid; Rhein CA Reg. No. : 478-43-3 (8S-cis)-8-Acetyl-10[(3-amino-2,3,6-trideoxy-alpha-L- lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11- trihydroxy-l-methoxy-5,12-naphthacenedione hydrochloride; Daunomycin hydrochloride CA Reg. No.: 20830-81-3 1,2, -Trihydroxyanthraquinone; Purpurin CA Reg. No. : 81-54-9 1-Aminoanthraquinone diazonium salt CA Reg. No.: 16048-40-1 2,2'-Dimethyl-[1,1 • -bianthracene]-9,9',10,10*-tetrone; 2,2*-Dimethyl-1,1'-bianthraquinone CA Reg. No. : 81-26-5 3-(D-apio-beta-D-Furanosyloxy)-1,8-dihydroxy-6-methyl- 9,10-anthracenedione; Frangulin B CA Reg. No.: 14101-04-3 2-Chloroanthraquinone CA Reg. No. : 131-09-9 1,5-Dichloroanthraquinone CA Reg. No.: 82-46-2 1, ,5,8-Tetrachloroanthraquinone CA Reg. No.: 81-58-3 1-Chloroanthraquinόne CA Reg. No.: 82-44-0 1,8-Dichloroanthraquinone CA Reg. No.: 82-43-9 2-Bromo-3-methylathraquinone CA Reg. No.: 84-44-6 2-(2,2,2-Trimethylpropionamido)anthraquinone CA Reg. No. : None 2,6-Bis[2-(dimethylamino)ethoxy]-9,10-anthracenedione; Tilorone analog R11,043DA CA Reg. No.: 66686-31-5 2-Methyl-l-nitroanthraquinone CA Reg. No.: 129-15-7 l-Amino-9,10-dihydro-9,10-dioxo-2-anthracenesulfonic acid; l-Aminoanthraquinone-2-sulfonic acid CA Reg. No. : 83-62-5 9,10-Dihydro-5-nitro-9,10-dioxo-l-anthracenesulfonic acid; 5-Nitroanthraquinone-l-sulfonic acid CA Reg. No.: 82-50-8 3-Chloro-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid; 2-Chloroanthraquinone-3-carboxylic acid CA Reg. No.: 84-32-2 50/50 Mixture of Anthrarufin and Danthron CA Reg. No.: None Anthraquinone CA Reg. No. : 84-65-1 1, 8-Dihydroxy-3- (hydroxymethyl) -anthraquinone ; Aloe- emodin CA Reg . No . : 481-72-1 7,16-Dichloro-6,15-dihydro-5,9,14,18-anthrazinetetrone; 7,16-Dichloroindanthrone CA Reg. No.: 130-20-1 1,2,3,4,5,8-Hexahydroxyanthraquinone; Alizarin cyanin CA Re . No. : None 2,4,5,7-Tetrabromo-l,8-dihydroxy-9,10-anthracenedione; 2,4,5,7-Tetrabromochrysazin CA Reg. No.: 17139-66-1 1,2,7-Trihydroxyanthraquinone; Anthrapurpurin CA Reg. No.: 602-65-3 1,4,5-Trihydroxy-2-methyl-9,10-anthracenedione; Islandicin CA Reg. No.: 476-56-2 1.4,5,7-Tetrahydroxy-2-methyl-9,10-anthracenedione; Catenarin 0 CA Reg. No.: 476-46-0 1,8-Dihydroxy-3-methoxy-6-methyl-9,10-anthracenedione; Physcion CA Reg. No. : 521-61-9 1,4,5,8-Tetrahydroxy-2-methyl-9,10-anthracenedione; 5 Cynodontin CA Reg. No.: 476-43-7 1.5,8-Trihydroxy-3-methyl-9,10-anthracenedione; Helminthosporin CA Reg. No.: 518-80-9 l-Hydroxy-2-[6-O-β-D-xylopyranosy1-β-D- " glycopyranosyl)oxy]-9,10-anthracenedione; Ruberythric άClu CA Reg. No. : 152-84-1 2-Phenoxy quinizarin-3,4'-disulfonic acid, di K salt CA Reg. No.: None 5 (+,-)-l-Acetoxy-8-hydroxy-l,4,4a,9a- tetrahydroanthraquinone CA Reg. No.: 73794-49-7 l-Amino- [ [4- [(dimethylamino)methylJphenyl]amino- 9,10-anthracenedione; Basic Blue 47 CA Reg. No.: 12217-43-5 0 1,5-Bis(2-carboxyanilino)-9,10-anthracenedione; Acridylic acid CA Reg. No.: 81-78-7 1,8-Dihydroxy-9-anthranol; 1,8-Dihydroxyanthranol CA Reg. No.: 480-22-8 5 1,2,10-Anthracenetriol; Anthrarobin CA Reg. No. : 577-33-3 l-Amino-4-bromo-2-methylanthranquinone CA Reg. No. : 81-50-5 1, -Diaminoanthraquinone CA Reg. No.: 128-95-0 2, 6-Diaminoanthraquinone CA Reg. No.: 131-14-6 l-Amino-4 [4-[[4-chloro-6[ [2,3, or 4-sulfophenyl]amino]- 1,3,5-triazin-2-yl]amino]-3-sulfophenyl]amino]-9,10- dihyro-9,10-dioxo-2-anthracenesulfonic acid; Reactive blue 2; Procion blue HB(S); Cibacron blue 3G-A; Basilen blue E-3G CA Reg. No.: 12236-82-7 Anthraquinone-1,5-disulfonic acid, di Na salt hydrate (95%) CA Reg. No.: 853-35-0 Anthraquinone-2,6-disulfonic acid, di Na salt CA Reg. No. : 84-50-4 Anthraquinone-2-sulfonic acid, sodium salt monohydrate CA Reg. No.: 131-08-8 1,2-Bis[ (4-sulfophenyl)amino]-4-hydroxyanthraquinone; Alizarin blue black B CA Reg. No.: 1324-21-6 3-Aminomethylalizarin-N,N-diacetic acid CA Reg. No.: 3952-78-1 2-Amino-4-[ [3-(ethenylsulfonyl)phenyl]-9,10-dihydro- 9, 10-dioxo]-2-anthracene sulfonic acid, monosodium salt; Acid blue 215 CA Reg. No.: 14541-90-3 1-(Methylamino)anthraquinone CA Reg. No. : 82-38-2 2, 2 « - [ (9, 10-Dihydro-5, 8-dihydroxy-9, 10-dioxo-l, 4- anthracendiyl) diimino] bis [5-methylbenzenesulf onic acid] , di Na salt ; Acid green 41 CA Reg . No . : 4430-16-4 2, 2 ' - [ (9, 10-Dihydro-9, 10-dioxo-l, 4- anthracenediyl) diimino] bis [5-butylbenzenesulfonic acid] ; CA Reg . No . : 6408-57-7 1,1*-Iminobis[4-amino]9,10-anthracenedione, sulfonated; Acid black 48 CA Reg. No.: 1328-24-1 l-Amino-9,10-dihydro-9,10-dioxo-4-(phenylamino)-2- anthracenesulfonic acid, Na salt; Acid blue 25 CA Reg. No.: 6408-78-2 4- [[4-(Acetylamino)phenyl]amino]-l-amino-9,10-dihydro- 9,10-dioxo-2-anthracenesulfonic acid, Na salt; Acid blue 40 CA Reg. No.: 6424-85-7 l-Amino-9,10-dihydro-9,10-dioxo-4-[[3[[2- (sulfoxy)ethyl]-sulfonyl]phenyl]amino]-2- anthracenesulfonic acid, disodium salt; Remazol Brilliant blue R; CA Reg. No.: 2580-78-1 l-Amino- [ [3-[4,6-dichloro-l,3,5-triazin-2-yl)amino]-4- sulfophenyl]amino]-9,10 dihydro-9,10-dioxo-2- anthracenesulfonic acid; Reactive blue 4 CA Reg. No.: 13324-20-4 1-(9,10-Dihydro-9,10-dioxo-l-anthracenyl-l,2- hydrazinedisulfonic acid, di Na salt; (1- Anthraquinonyl)-1,2-hydrazine disulfonic acid, di Na salt CA Reg. No.: 54345-83-4 9,10-Dihydro-5,6-dihydroxy-9,10-dioxo-l- anthracenesulfonic acid; Alizarin-5-sulfonic acid CA Reg. No.: 6373-42-8 N-(4-Chloro-9,10-dihydro-9,10-dioxo-l- anthracenyl)benzamide; l-Benzamido-4-chloroanthraquinone CA Reg. No. : 81-45-8 l-Amino-4-bromo-9,10-dihydro-9,10-dioxo-2- anthracenesulfonic acid, Na salt; l-Amino-4- bromoanthraquinone-2-sulfonic acid, Na salt CA Reg. No.: 6258-06-6 l-Amino-9,10-dihydro-4[[(4-methylphenyl)sulfonyl]a ino- 9,10-dioxo-2-anthracenesulfonic acid, Na salt; 1-Amino- 4-(p-toluenesulfonamido)anthraquinone-2-sulfonic acid, Na salt CA Reg. No.: 64981-00-6 S,10-Dihyuro-9,10-dioxo-2,3-anthracenedιcarboxylic acid CA Reg. No.: 27485-15-0 1,1'-Iminobis(4-nitro-9,10-anthracenedione) CA Reg. No. : 128-88-1 l-Amino-4-chloro-2-methylanthraquinone CA Reg. No.: 3225-97-6 2,3-dimethyl-l,4-dihydroxyanthraquinone; 2,3- Dimethylquinizarin CA Reg. No.: 25060-18-8 6-Methyl-l,3,8-trihydroxyanthraquinone; Emodin CA Reg. No. : 518-82-1 1,4-Bis(methylamino)-anthraquinone CA Reg. No.: 2475-44-7 N-(4-Amino-9,10-dihydro-3-methoxy-9,10-dioxo-l- anthracenyl)-4-methylbenzenesulfonamide; N-(4-Amino- 3-methoxyanthraquinone-l-yl)-p-toluenesulfonamide; 1- Amino-2-methoxy-4-(p-tolysufonamido)anthraquinone CA Reg. No.: 81-68-5 [l,l'-Bianthracene]-9, 9'10,10'-tetrone; 1,1'- Bianthraquinone CA Reg. No.: 914-20-5 6,7-Dichloro-l,4-dihydroxyanthraquinone CA Reg. No.: 1225-15-6 7- I [9, 10-Dihydro-4-(methylamino)-9,10-dioxo-l- anthracenyl]amino]-5-methyl-benzenesulfonic acid, monosodium salt; Alizarine astrol B-CF CA Reg. No.: 6408-51-1 2,8-Diphenyl-anthra[2,1-d:6,5-d']bisthiazole-6,12-dione; Indanthrene yellow GCN CA Reg. No. : 129-09-9 2-Methoxy-3-methyl-9,10-anthracenedione CA Reg. No.: 17241-42-8 1,4-Bis[(1-methylethyl)amino]-9,10-anthracenedione; 1,4-Di(isopropylamino)anthraquinone CA Reg. No.: 14233-37-5 1,4-Bis[(2,4, 6-triethylphenyl)amino]-9,10- anthracenedione; 1,4-Bis(2,4,6- triethylanilino)anthraquinone CA Reg. No.: 116-74-5 1-(2-Hydroxyethyl)amino-4-methylaminoanthraquinone; Disperse blue 3 CA Reg. No.: 2475-46-9 1, -Bis[(4-methylphenyl)amino]9,10-anthracenedione; Solvent green 3 CA Reg. No.: 128-80-3 2-Amino-3-hydroxyanthraquinone CA Reg. No.: 117-77-1 1-(Bromothio)anthraquinone CA Reg. No. : None 1,8-Bis(phenylmethoxy)-9,10-anthracenedione; 1,8-Dibenzyloxyanthraquinone CA Reg. No.: 69595-66-0 l-Amino-2-(2-aminoethylthio)-4-hydroxyanthraquinone CA Reg. No. : None 1,4-Bis(pentylamino)-9,10-anthracenedione; Oil blue N CA Reg. No.: 2646-15-3 l-Amino-2-bromo-4-hydroxyanthraquinone CA Reg. No.: 116-82-5 2-Propiσnamidoanthraquinone CA Reg. No. : None 1,4-Diamino-2,3-bis(2-phenoxyethoxy)anthraquinone CA Reg. No.: 41313-11-5 N-(5-Chloro-9,10-dihydro-9,10-dioxo-l- anthraceny1)benzamide; l-Benzamido-5- chloroanthraquinone CA Reg. No.: 117-05-5 Anthraquinone-1-arsonic Acid CA Reg. No. : None N,N'-[Iminobis(9,10-dihydro-9,10-dioxo-4,1- anthracenediy1) ]-bisbenzamide; 4,4'-Dibenzamido-1,1'- dianthrimide CA Reg. No.: 128-79-0 1,4,5,8-Tetraaminoanthraquinone; Disperse blue 1 CA Reg. No.: 2475-45-8 2-MethyIanthraquinone CA Reg. No.: 84-54-8 9,10-Dihydro-9,10-dioxo-2,7-anthracenedisulfonic acid, di Na salt; Anthraquinone-2,7-disulfonic acid, di Na salt CA Reg. No.: 853-67-8 1, 2, 3-trihydroxyanthraquinone; Anthragallol CA Reg. No . : 602-64-2 Carmine (Aluminum lake) CA Reg . No . : 1390-65-4 9,10-Dihydro-l,4-dihydroxy-9,10-dioxo-2- anthracenesulfonic acid CA Reg. No.: 145-48-2 2-Amino-3-chloroanthraquinone CA Reg. No.: 84-46-8 1-Anthraquinonesulfonic acid, Na salt CA Reg. No.: 128-56-3 2-tert-butylanthraquinone CA Reg. No. : 84-47-9 1,4-Dihydroxyanthraquinone CA Reg. No. : 81-64-1 1,5-Diamino-4,8-dihydroxyanthraquinone CA Reg. No.: 145-49-3 l-Hydroxy-4-[(4-methylphenyl)amino]-9,10- anthracenedione; l-Hydroxy-4-(p-toluidino)- anthraquinone CA Reg. No. : 81-48-1 1,4-Dimethylanthraquinone CA Reg. No.: 1519-36-4 1,1*-Iminobis-9,10-anthracenedione; Dianthrimide CA Reg. No.: 82-22-4 2-(Cyclopropylcarboxamido)anthraquinone CA Reg. No. : None l-Amino-2-methylanthraquinone; Disperse orange 11 CA Reg. No. : 82-28-0 2-[ (9,10-Dihydro-4-hydroxy-9,10-dioxo-l- anthracenyl)amino]-5-methyl-benzenesulfonic acid, Na salt; Solway purple R CA Reg. No.: 4430-18-6 2,2'-[ (9,10-Dihydro-5,8-dihydroxy-9,10-dioxo-l,4- anthracenediyl)diimino]bis[5-methyl]benzenesulfonic acid; alizarine viridine CA Reg. No.: 4430-16-4 l,4-Bis(ethylamino)-9,10-anthracenedione; Sudan blue CA Reg. No.: 6994-46-3 1,4-Diamino-5-nitroanthraquinone CA Reg. No.: 82-33-7 N-Benzyl-9,10-dihydro-9,10-dioxo-2-anthracenesulfonamide CA Reg. No. : None 2-Bromoanthraquinone CA Reg. No. : 572-83-8 1-Fluoroanthraquinone CA Reg. No. : 569-06-2 1-Cyanoanthraquinone CA Reg. No.: 38366-32-4 2-Trifluoromethylanthraquinone CA Reg. No.: 362-21-0 3. A process for inhibiting sulfide production by sulfate- reducing bacteria comprising contacting the medium containing the sulfate-reducing bacteria with a mixture of at least two or more compounds listed in Claim 2. 4. The process of Claim 2 wherein the compound is 1,8-dihydroxyanthraquinone. 5. The process of Claim 2 wherein the compound is 1-chloroanthraquinone or 2-chloroanthraquinone. 6. The process of Claim 2 wherein the compound is 3-chloro-2-anthraquinone carboxylic acid. 7. The process of Claim 2 wherein the compound is 2-bromoanthraquinone. 8. The process of Claim 2 wherein the compound is 1-fluoroanthraquinone. 9. The process of Claim 2 wherein the compound is 1-cyanoanthraquinone. 10. The process of Claim 2 wherein the compound is 2-methyl-trifluoroanthraquinone. 11. The process of Claim 1 or 2 wherein the sulfate-reducing bacterium comprises one or more of Desulfovibrio desulfuricans. β. salexiσens. £. vulσaris. R. nultispirans, or £___ g gas . 12. The process of Claim 1 or 2 wherein the compound is dissolved or suspended in a solvent prior to contact with the medium. 13. The process of Claim 12 wherein the solvent comprises one or more of water, ethanol, acetone, methanol, dimethylsulfoxide, dimethylformamide, or tetrahydrofuran, or other water-miscible solvents. 14. The process of Claim 1 or 2 wherein the compound is contacted with the medium at a concentration of at least about 0.1 ppm. 15. The process of Claim 1 or 2 further comprising addition of a reducing agent to the medium containing the sulfate-reducing bacteria = 16. The process of Claim 15 wherein the reducing agent is sodium sulfide and is present in the medium at a concentration of from about 2 to about 4 mM. 17. The process of Claim 1 or 2 used for waste treatment. 18. The process of Claim 1 or 2 used to reduce the growth of sulfate-reducing bacteria. 19. An automated process for testing a compound for its ability to inhibit sulfide production by bacteria comprising a) maintaining a culture of sulfate-reducing bacteria in exponential growth phase by chemostat culture; b) contacting in an automated analyzer a solution of the compound to be tested with an aliquot of said culture of step a); c) adding to the compound and culture a substrate to initiate sulfide production; d) incubating the culture, compound and substrate mixture to permit sulfide production; and e) measuring the amount of sulfide produced. 20. The process of Claim 19 further comprising repeating steps b) through d) . 21. The process of Claim 19 wherein the sulfate- reducing bacterial culture is contacted with an inert gas to reduce any background sulfide level prior to contact with the compound to be tested. 22. The process of Claim 19 wherein the compound to be tested is delivered from an automated sampler into a bacterial culture stream. 23. The process of Claim 19 wherein the substrate comprises a mixture of a lactate, sulfate and a surfactant. 24. The process of Claim 23 wherein the substrate comprises a mixture of 10 mM sodium lactate, 5mM sodium sulfate and from 0.1% to 0.2% final concentration using a 30% stock solution by volume of Brij 35®. 25. The process of Claim 19 wherein the combination of substrate, bacteria culture, and compound to be tested is acidified to a pH of about 4.5 prior to separation by means of a silicone membrane. 26. The process of Claim 19 further comprising determining the level of background sulfide present in a combination of the culture and substrate in water. 27. The process of Claim 19 conducted under anaerobic conditions. 28. The automated process depicted in Figure 1.

Inventors: ANDERSON ALBERT GORDON, COOLING FREDERICK BEISWANGER I, ODOM JAMES MARTIN, WEIMER PAUL JAMES, ANDERSON, ALBERT, GORDON, COOLING, FREDERICK, BEISWANGER, III, ODOM, JAMES, MARTIN, WEIMER, PAUL, JAMES
Applicants: DU PONT, E.I. DU PONT DE NEMOURS AND COMPANY
Application year: 1991
Main classification: A01N35
IPC codes: A01N35, C12Q1